The Record header image

Subscribe  |  The Record Archive  |  Contacts  |  bcbsm.com

April 2023

All Providers

Blue Cross works with Quartet to connect behavioral health providers with members, starting July 1, 2023

Action item

Learn how we’re working with Quartet to help members access behavioral health care and how you can join the Quartet online platform.

Blue Cross Blue Shield of Michigan has contracted with Quartet, an independent company that offers an online care navigation solution. The company connects behavioral health providers with new patients through an online platform at no cost to the provider or patient.

We know that some of our members struggle to find the behavioral health care they need. Our relationship with Quartet is designed to help our members who are having difficulty obtaining timely care from a behavioral health specialist in their area access outpatient behavioral health services with an appropriate provider more quickly.

Starting July 1, 2023, Quartet will begin referring members seeking outpatient treatment to behavioral health providers registered on Quartet’s platform, based on their clinical specialty and their availability.

Quartet’s services will be available to the following adult members (18 years of age or older) who reside in Michigan:

  • Fully insured Blue Cross commercial members
  • Fully insured Blue Care Network commercial members
  • All BCN Advantage℠ members
  • Select Medicare Plus Blue℠ members

Through Quartet, a behavioral health provider can receive referrals, accept new patients, track the patient’s progress and access clinical assessments and other resources.

Joining the Quartet online platform

Beginning April 2023, Quartet will begin reaching out to Blue Cross and BCN participating behavioral health providers to assist them with joining the Quartet online platform. Participation is voluntary. We hope our behavioral health providers are encouraged to join and will see the value in this tool for both practitioners and patients.

Here’s how Quartet works

  1. Quartet works with the provider to create a profile and get added to the platform.
  2. Quartet matches members seeking outpatient behavioral health care to a provider based on their geographic location, treatment needs and preferences. Quartet can refer members to both in-person and virtual care.
  3. Quartet sends a referral to the selected provider through the platform for a specific member.
  4. The provider reviews and accepts or declines the referral.
  5. When the provider accepts the referral, the provider contacts the member to schedule an appointment.

Please visit quartethealth.com/mental-health-providers** for more information, to schedule a demo or if you would like to sign up.

Quartet is an independent company contracted by Blue Cross Blue Shield of Michigan to connect Blue Cross and BCN members seeking outpatient behavioral health services with the appropriate behavioral health providers.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


What to do when voluntary prior authorization ends May 1

The February 2023 issue of The Record announced the end of voluntary prior authorization requests in the article “Voluntary prior authorization ends May 1.”

If you have a procedure coming up for a Blue Cross Blue Shield of Michigan patient after May 1 and you’re not sure whether it will be covered or not, here are some steps you should take:

  1. Check eligibility and benefits — First, make sure the patient’s coverage is in effect and the procedure is a covered benefit. You can do this within our provider portal at availity.com** by clicking on Eligibility and Benefits Inquiry. If additional details are available within Benefit Explainer, you’ll see a link to Benefit Explainer near the logo toward the top of the member’s benefits screen.
  2. Check if prior authorization is required — Within our provider portal, click on Authorization Request in the Patient Registration drop-down menu. Complete the information for the specific patient and procedure. This application will tell you if a prior authorization is required and, if so, where to submit the request.
  3. Check medical policy — Check for further coverage details within the medical policy. Go to Medical Policy Router Search and type in a keyword or procedure code to learn more about medical policy coverage.
  4. Contact Provider Inquiry — If coverage of the procedure is still not clear, contact Provider Inquiry for assistance:
    • Professional: 1-800-344-8525
    • Facility: 1-800-249-5103

Some procedures require prior authorization

Blue Cross requires prior authorization for some procedures. You can determine whether a procedure requires prior authorization for a specific patient by using the Authorization Request application described in Step 2 above. You can also reference the following resources for a summary of prior authorization requirements:

Availity is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


Prior authorization changes coming in June

Michigan’s prior authorization law requirements** go into effect on June 1, 2023. These requirements apply to health care insurers and providers in Michigan for members who have commercial coverage.

These requirements aim to give members and health care providers a clearer understanding of the services that require prior authorization and of the prior authorization criteria for medical and pharmacy benefits.

The areas that will be affected are:

        

Area

       

Requirements of the law

Services and benefits that require prior authorization and medical necessity criteria

The following must be posted to a publicly available website:

  • A list of all services and benefits that require prior authorization
  • Medical necessity criteria for all benefits

This information must be posted as follows:

  • For medical services: 60 days in advance of changes
  • For pharmacy services: 45 days in advance of changes, with some exceptions for patient safety

Note: While this information is currently available to Blue Cross Blue Shield of Michigan and Blue Care Network members and providers, we’re working to consolidate it, make it more easily accessible and present it in more easily understandable language.
The law also requires insurers to modify prior authorization requirements based on provider performance. We already have several gold carding programs in place that meet this requirement.

Turnaround times

Turnaround times for prior authorization requests will change.

  • For standard prior authorization requests: We must make determinations on requests or ask for additional information as follows:
    • Within 9 days of submission, for requests submitted on or after June 1, 2023
    • Within 7 days of submission, for requests submitted on or after June 1, 2024
  • For urgent*** prior authorization requests: We must make determinations on requests or ask for additional information within 72 hours of submission for requests submitted on or after June 1, 2023.

Note: If we ask for additional information, providers should submit it as soon as possible. Once the provider submits the additional information, the turnaround time noted above will reset. For example, we must make a determination within 72 hours of receiving additional information for an urgent request.
Approved prior authorization requests will be valid for a minimum of 60 days or for the length of time that’s clinically appropriate, whichever is longer.
As is true now, providers and members will be able to appeal prior authorization requests that aren’t approved.

Electronic prior authorizations

Insurers must provide an online method through which providers can submit prior authorization requests for all services, including prescription drugs. Online submission methods include our e‑referral tool, online tools provided by vendors who manage certain authorizations on our behalf and electronic prior authorization, or ePA, tools.
Notes:

  • We’ll continue to provide alternate submission methods (fax or phone) for times when providers are unable to submit requests online due to power outages, internet outages and so on.
  • For members who have Blue Cross commercial coverage through MESSA, providers must submit prior authorization requests to MESSA for certain services. Starting June 1, there will be a new process for providers to submit these requests online for MESSA members. Look for additional information in upcoming provider alerts and issues of The Record.

Reporting

Insurers must submit reports about prior authorizations annually to the Michigan Department of Insurance and Financial Services, or DIFS, on June 1 of each year, beginning in 2023.
Reporting will include the number of prior authorization requests that weren’t submitted to us using an online submission method.

Member appeals

We’ll communicate details before June 1.


These requirements also apply to the third-party vendors with which Blue Cross and BCN have contracted to manage prior authorizations for certain services. We’re working with these vendors to ensure compliance with the law.

As we make changes, we’ll publish provider alerts and newsletter articles with additional information. For example, we announced in the February issue of The Record that voluntary prior authorization ends on May 1.

Be sure to check member eligibility and benefits through our provider portal (availity.com)** or Provider Inquiry prior to performing services.

Availity is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.

***A request for medical care or services is considered urgent when the time frame for making determinations for routine or non-life-threatening care would do one of the following:

  1. Seriously jeopardize the life or health of the member or the member’s ability to regain maximum function, based on a layperson’s judgment.
  2. Seriously jeopardize the life, health or safety of others, due to the member’s psychological state.
  3. Subject the member to adverse health consequences without the care or treatment that is the subject of the request, in the opinion of a practitioner who has knowledge of the member’s medical or behavioral condition.

We’re updating COVID-19 provider communications in preparation for end of public health emergency

On Jan. 30, 2023, the federal government announced it will end the public health emergency on May 11.

Blue Cross Blue Shield of Michigan and Blue Care Network enacted temporary measures to support health care providers and protect members during the COVID-19 pandemic. We’ve been updating the Temporary changes due to the COVID-19 pandemic document as we determine which temporary changes become permanent and which will end.

We’ll continue to update the document as we make policy decisions.

As a reminder, here’s how you can view our COVID-19 provider communications:

  1. Log in to our provider portal (availity.com).**
  2. Click on Payer Spaces in the menu bar, then click on the BCBSM and BCN logo.
  3. Click on the Resources tab.
  4. Click on Secure Provider Resources (Blue Cross and BCN).
  5. Under Easy Access, click on Coronavirus information.

You can also access these communications on our public website on the COVID-19 webpage for health care providers.

Continue to look for additional communications as we prepare for the end of the public health emergency.

Availity is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


Here’s how to determine prior authorization requirements for patients with non-Michigan Blue plans

Michigan providers can find information about prior authorization requirements for patients with non-Michigan Blue plans as follows:

  • Specific information may be available through Availity®. See the “Specific information” section below for details.
  • General information is available through our Medical Policy & Pre-Cert/Pre-Auth Router. See the “General information” section later in this article for details.

Specific information

Specific information about prior authorization requirements may be available through Availity.

  1. Log in to our provider portal at availity.com.**
  2. Click on Patient Registration and then click on Authorizations & Referrals.

  1. Click on Authorization Request.

  1. In the Select a Payer screen, make these selections:

Field

Selection

Organization

Select the appropriate organization.

Payer

Select BCBS Michigan and Blue Care Network.

Request Type

Select the appropriate type of request.


  1. Click on Next.
  2. In the Select a Patient field, choose any patient.
  3. In the Member ID field, enter the subscriber ID from the non-Michigan member’s ID card. Be sure to include the three-character alpha prefix.
  4. Complete the fields in the Requesting Provider section and click Next.
  5. Based on what you see on the screen, complete the rest of the steps.

What you see on screen

What to do

“Important: You have been routed from BCBSM Michigan and Blue Care Network to BCBSXX to conduct pre-service review for a BCBSXX member.”

  1. Click on the Inpatient Authorization or Outpatient Authorization link.
  2. The Authorizations page opens to the Requesting Provider section.

  3. Scroll up to the Patient Information section at the top of the screen.
  4. Enter the non-Michigan member’s member ID, relationship to the subscriber, first and last name and date of birth.
  5. Enter the appropriate information in all required fields.

A Blue Cross Blue Shield Association disclaimer that states: “You are about to be redirected to a third-party site, which may require a separate log-in…”

  • Click Submit.
  • Follow the instructions in the screen that opens.

General information

For general information about services that require authorization, go to our Medical Policy & Pre-Cert/Pre-Auth Router. To access the router:

  1. Go to bcbsm.com/providers.
  2. Click on Resources.
  3. Click on the out-of-area router link.
  4. Click on the General pre-certification/pre-authorization information option.
  5. Enter the three-character alpha prefix from the non-Michigan member’s subscriber ID in the Prefix field.
  6. Click on Go.

Additional information

You can also find this information in the Determining prior authorization requirements for a member document. That document also explains how:

  • Michigan providers can look up requirements for patients who have coverage through Blue Cross Blue Shield of Michigan or Blue Care Network plans.
  • Non-Michigan providers can look up requirements for patients who have coverage through Blue Cross Blue Shield of Michigan or Blue Care Network plans.

You can access this document by clicking on the Determine prior authorization requirements for members tile on the left side of any page of our ereferrals.bcbsm.com website.

Availity is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


2023 CPT code update: New and deleted codes

Pathology and laboratory

Code

Change

Coverage comments

Effective date

0364U

Added

Not covered

April 1, 2023

0365U

Added

Not covered

April 1, 2023

0366U

Added

Not covered

April 1, 2023

0367U

Added

Not covered

April 1, 2023

0368U

Added

Not covered

April 1, 2023

0369U

Added

Not covered

April 1, 2023

0370U

Added

Not covered

April 1, 2023

0371U

Added

Not covered

April 1, 2023

0372U

Added

Not covered

April 1, 2023

0373U

Added

Not covered

April 1, 2023

0374U

Added

Not covered

April 1, 2023

0375U

Added

Not covered

April 1, 2023

0376U

Added

Not covered

April 1, 2023

0377U

Added

Not covered

April 1, 2023

0378U

Added

Not covered

April 1, 2023

0379U

Added

Not covered

April 1, 2023

0380U

Added

Not covered

April 1, 2023

0381U

Added

Not covered

April 1, 2023

0382U

Added

Not covered

April 1, 2023

0383U

Added

Not covered

April 1, 2023

0384U

Added

Not covered

April 1, 2023

0385U

Added

Not covered

April 1, 2023

0386U

Added

Not covered

April 1, 2023

0324U

Deleted

Deleted March 31, 2023

March 31, 2023

0325U

Deleted

Deleted March 31, 2023

March 31, 2023

Category III codes
Surgery

Code

Change

Coverage comments

Effective date

0793T

Added

Not covered

July 1, 2023

0795T

Added

Not covered

July 1, 2023

0796T

Added

Not covered

July 1, 2023

0797T

Added

Not covered

July 1, 2023

0798T

Added

Not covered

July 1, 2023

0799T

Added

Not covered

July 1, 2023

0800T

Added

Not covered

July 1, 2023

0801T

Added

Not covered

July 1, 2023

0802T

Added

Not covered

July 1, 2023

0803T

Added

Not covered

July 1, 2023

0805T

Added

Not covered

July 1, 2023

0806T

Added

Not covered

July 1, 2023

0809T

Added

Not covered

July 1, 2023

0810T

Added

Not covered

July 1, 2023

Category III codes
Radiology

Code

Change

Coverage comments

Effective date

0807T

Added

Not covered

July 1, 2023

0808T

Added

Not covered

July 1, 2023

Category III codes
Other medical services

Code

Change

Coverage comments

Effective date

0792T

Added

Not covered

July 1, 2023

0794T

Added

Not covered

July 1, 2023

0804T

Added

Not covered

July 1, 2023

Category III codes
Physical therapy

Code

Change

Coverage comments

Effective date

0791T

Added

Not covered

July 1, 2023

None of the information included in this article is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with all applicable state and federal laws and regulations.


Billing chart: Blue Cross highlights medical, benefit policy changes

You’ll find the latest information about procedure codes and Blue Cross Blue Shield of Michigan billing guidelines in the following chart.

This billing chart is organized numerically by procedure code. Newly approved procedures will appear under the New Payable Procedures heading. Procedures for which we have changed a billing guideline or added a new payable group will appear under Updates to Payable Procedures. Procedures for which we are clarifying our guidelines will appear under Policy Clarifications. New procedures that are not covered will appear under Experimental Procedures.

We'll publish information about new Blue Cross groups or changes to group benefits under the Group Benefit Changes heading.

For more detailed descriptions of the Blue Cross' policies for these procedures, check under the Commercial Policy tab in Benefit Explainer on Availity®. To access this online information:

    1. Log in to availity.com.
    2 .Click on Payer Spaces on the Availity menu bar.
    3. Click on the BCBSM and BCN logo.
    4. Click on Benefit Explainer on the Applications tab.
    5. Click on the Commercial Policy tab.
    6. Click on Topic.
    7. Under Topic Criteria, click on the circle for Unique Identifier and click the drop-down arrow next to Choose Identifier Type, then click on HCPCS Code.
    8. Enter the procedure code.
    9. Click on Finish.
    10. Click on Search.
Code* BCBSM changes to:
Basic Benefit and Medical Policy, Group
Variations Payment Policy, Guidelines
POLICY CLARIFICATIONS

00170,** 41899** **Unlisted procedure code

Dental anesthesia

The safety and efficacy of general anesthesia or intravenous sedation for specified dental procedures have been established. They are useful therapeutic options for patients meeting the appropriate patient selection criteria.

Inclusionary and exclusionary criteria have been updated, effective March 2023.

Inclusions:

This policy addresses general anesthesia provided for rendering dental services. General anesthesia services for rendering a dental procedure can be eligible for separate reimbursement if the anesthesia is rendered by a provider other than the dental services provider (such as an anesthesiologist or certified registered nurse anesthetist, or CRNA). All facility charges incurred in association with the anesthesia charges are covered under the medical/surgical benefit if any one of the following criteria are met:

  • For children younger than age 7 (i.e., through the end of the sixth year)
  • For older patients (age 7 and older), consider the extent of the procedures required. At a minimum, the patient should require one of the following:
    • A total of six or more teeth to be extracted
    • Procedures that must be performed in two or more quadrants of the mouth on the same date of service

In addition, for patients ages 7 and older, one of the following conditions must exist:

  • A concurrent hazardous medical or behavioral condition that creates a documented medical necessity for performing the procedure in an accredited facility using general anesthesia or sedation. These conditions may include, but are not limited to, labile hypertension, significant cardiac arrhythmias (more than five premature ventricular contractions per minute on EKG), severe cerebral palsy or spasticity, morbid obesity, severe autism, movement disorders, chronic respiratory disease, hemophilia, uncontrolled diabetes, etc. Note: A history of chronic diabetes mellitus isn’t considered a concurrent hazardous medical condition under the above criteria.
  • A statement from the member’s primary physician supporting that the member has medical conditions too serious to undergo dental treatment in the dental office setting.
  • Significant cellulitis or swelling and associated trismus (a sustained spasm of the jaw muscles, characteristic of the early stages of tetanus) that doesn’t allow the use of local anesthesia.
  • Extensive orofacial or dental trauma for which treatment under local anesthesia would be ineffective or compromised.

Exclusions:

  • Patients with situational anxiety or stable chronic medical conditions don’t satisfy the above criteria.
  • All other anesthesia modalities used to perform dental services in the dental provider’s office.

0172U, 0037U, 81191, 81192, 81193,
81194, 81210, 81301, 81445, 81450,
81455, 81479**

**Not otherwise classified procedure

Basic benefit and medical policy

NGS testing of multiple genes for malignant conditions

Next-generation sequence testing of certain clinically useful genes, through a multiple-gene panel, may be considered established for metastatic or advanced (inoperable, locally advanced or locally recurrent) solid cancers or hematolymphoid cancers for diagnostic and prognostic purposes, and in guiding the selection of appropriate therapeutic options, when criteria are met.

Inclusionary and exclusionary criteria have been updated. Procedure code *0172U was changed to a payable service effective Jan. 1, 2023, to reflect policy updates. Procedure codes *0037U, *81210 and *81479 were added as established procedures.

Payment policy:

Not payable in an office location

Modifiers 26 and TC aren’t applicable.

Inclusions:

Hematolymphoid cancer

Next-generation sequencing, or NGS, with a multiple-gene panel test (e.g., CPT code *81445, *81450 or *81455), may be considered established when used for diagnostic and prognostic purposes or for guidance in the selection of appropriate FDA therapeutic options for the following conditions:

  • Suspected hematolymphoid neoplasms supported by clinical records that reflect an inconclusive diagnosis despite the clinical history, physical examination findings, blood work (e.g., CBC with peripheral smear, chromosome analysis)
  • Acute lymphoblastic leukemia
  • Acute Myelogenous Leukemia
  • B-acute lymphocytic leukemia
  • B-cell Non-Hodgkin lymphoma
  • Chronic lymphocytic leukemia
  • Chronic myeloid leukemia
  • Myelodysplastic syndrome
  • Essential thrombocythemia or thrombocytosis
  • Plasma cell dyscrasia
  • Pediatric hematologic malignancies
  • Polycythemia vera
  • Primary myelofibrosis, known as PMF or Pre-PMF, or suspicion for PMF
  • T-acute lymphocytic leukemia
  • T-cell lymphoma, peripheral

Solid cancers

Next-generation sequencing, or NGS, with a multiple-gene panel test (e.g., CPT code *81445, *81450 or *81455) may be considered established when used for diagnostic and prognostic purposes or for guidance in the selection of appropriate FDA therapeutic options for any of the following conditions:

  • Metastatic cancers
  • Inoperable locally advanced cancers
  • Refractory cancers
  • Recurrent cancers
  • When diagnosis can’t be made by histopathologic means alone (e.g., sarcomas, neurologic neoplasms, etc.)
  • NGS testing for adjuvant therapy in non-advanced cancers may be considered, if consistent with FDA-approved indications

Tumor agnostic therapy

Next-generation sequencing, or NGS, with a multiple-gene panel test may be considered established when the following criteria are met:

  • Adult and pediatric individuals with metastatic or unresectable solid tumors and with disease progression following prior treatment and for whom there are no satisfactory alternative options

Tumor agnostic therapy is established for the following genetic variants:

  • BRAF V600E or V600K variants
  • Mismatch repair deficient, known as dMMR, or microsatellite instability-high, known as MSI-H
  • Tumor mutational burden-high, known as TMB-H (≥10 mutations/mega base [mut/Mb])
  • Neurotrophic tyrosine receptor kinase (NTRK 1/2/3) gene fusion

FDA-approved companion diagnostic tests

These include:

  • Tests that are billed with CPT codes (most laboratories are able to process these)
  • Proprietary laboratory analysis, or PLA, tests (processed by one specific independent laboratory). Most PLA tests have billing codes that end in “U.”

Proprietary laboratory analyses, or PLA, testing

A PLA test is considered established when all the following criteria are met:

  • Biomarker confirmation is required by an FDA-approved or FDA-cleared test prior to initiating treatment (as described in the FDA prescribing label of the therapeutic in the section “Indications and Usage”)
  • The test is an FDA-approved companion diagnostic
  • The FDA hasn’t identified a non-PLA test (e.g., an FDA companion diagnostic that is billed by a CPT code) for the same therapeutic indication.

Example when a PLA test isn’t medically necessary:

  • For melanoma, for the biomarker BRAF, for treatment with trametinib (Mekinist), the FDA-approved companion diagnostic tests are THxID BRAF Kit and FoundationOne®CDx. The THxID BRAF test isn’t a PLA test and has a CPT billing code; therefore, FoundationOne®CDx is considered not medically necessary and should not be selected as the companion diagnostic test.

Examples when an FDA-approved companion diagnostic PLA test is considered medically necessary (based on companion diagnostic information found on the FDA site Nov. 18, 2022):

  • BRAF V600: For melanoma, for combination treatment of Tecentriq, Cotellic and Zelboraf, FoundationOne®CDx is appropriate.
  • Microsatellite instability-high, or MSI-H: For solid tumors, for treatment with pembrolizumab (Keytruda), MSI-High, FoundationOne®CDx is appropriate.
  • Tumor mutational burden, or TMB, testing: For solid tumors, for treatment with pembrolizumab (Keytruda), TMB ≥ 10 mutations per megabase, FoundationOne®CDx is appropriate.

All above examples are based on FDA information found on the FDA site on Nov. 18, 2022; this information is subject to change by the FDA and should be verified.

Exclusions:

  • Next-generation sequencing, with multiple-gene panel testing (5 to 50 genes or 51 or more genes) when the above criteria aren’t met
  • Concurrent ordering of more than one multiple-gene panel test

15271-15278, 15777, A2001, A2002, A2004-A2018, A4100, A6010, A6011, A6021-A6023, Q4101-Q4108, Q4110, Q4113, Q4114, Q4116-Q4118, Q4121, Q4122, Q4124, Q4127, Q4128, Q4130, Q4135, Q4136, Q4147, Q4149, Q4158, Q4161, Q4164-Q4166, Q4182, Q4195, Q4196, Q4203

Experimental:

Q4111, Q4112, Q4115, Q4123, Q4125, Q4126, Q4134, Q4141-Q4143, Q4146, Q4152, Q4167, Q4175-Q4180, Q4193, Q4197, Q4202, Q4200, Q4220, Q4222, Q4226, Q4238

Basic benefit and medical policy

Skin and tissue substitutes

The safety and effectiveness of skin and tissue substitutes approved by the U.S. Food and Drug Administration and the Centers for Medicare & Medicaid Services have been established for patients meeting specified selection criteria. They may be useful therapeutic options when indicated.

Human tissue products are subject to the rules and regulations of banked human tissue by the American Association of Tissue Banks, or AATB, and have been established for patients meeting specified selection criteria. They may be useful therapeutic options when indicated.

Inclusionary criteria have been updated, effective March 1, 2023.

Inclusions:

The following skin and tissue substitutes are considered established when used according to FDA approval. This list may not be all-inclusive:

  • Apligraft®
  • Apis®
  • Atlas Wound Matrix
  • Biobrane®
  • Bio-conneKt® Wound Care Matrix
  • BTM Wound Dressing (aka NovoSorb® BTM)
  • Cytal® Burn Matrix
  • Cytal® MicroMatrix™
  • Cytal™ Wound Matrix (formerly MatriStem)
  • Cytal® Wound Sheet
  • Derma-Gide (aka Geistlich Derma-Gide™)
  • Dermagraft®
  • Endoform Dermal Template™
  • Epicel® has FDA Humanitarian Device Approval
  • E-Z Derm™
  • Helicoll™
  • Hyalomatrix®
  • InnovaMatrix™ (also known as InnovaMatrix AC)
  • InnovaMatrix™ FS
  • Integra® Bilayer Matrix
  • Integra® Dermal Regeneration Template
  • Integra® Flowable Wound Matrix
  • Intregra® Matrix Wound Dressing (formerly known as Avagen)
  • Keratec Wound Dressings (Kermatrix®):
  • Keratec Keragel
  • Keraderm
  • Kerafoam
  • Kerecis™ Omega3 Wound (formerly known as MeriGen)
  • MediSkin®
  • Microlyte® Ag
  • MicroMatrix®
  • Mirragen™
  • Oasis® Burn Matrix
  • Oasis® Ultra Tri-Layer Wound Matrix
  • Oasis® Wound Matrix
  • Ologen™ Collagen Matrix
  • Omeza® Collagen Matrix
  • OrCel®
  • PELNAC™ Bilayer Wound Matrix
  • Permacol™ (Covidien)
  • PermeaDerm B
  • PermeaDerm C
  • PermeaDerm Glove
  • Phoenix™ Wound Matrix
  • PriMatrix™ Dermal Repair Scaffold
  • Puracol® and Puracol® Plus Collagen Wound Dressings
  • PuraPly Wound Matrix (formerly known as FortaDerm)
  • PuraPly Antimicrobial Wound Matrix (formerly known as FortaDerm AM)
  • Restrata®
  • Strattice™
  • Suprathel®
  • SupraSDRM Biodegradable Matrix Wound Dressing
  • SurgiMend®
  • Symphony™
  • Talymed™
  • TenoGlide™
  • TransCyte®
  • XCelliStem® Wound Powder

Breast reconstructive surgery using allogeneic acellular dermal matrix productsa (including each of the following: AlloDerm®, AlloMend®, Cortiva®, [AlloMax™], DermACELL™, DermaMatrix™, FlexHD®, FlexHD® Pliable™, Graftjacket®) are considered established when one of the following are met:

  • There is insufficient tissue expander or implant coverage by the pectoralis major muscle and additional coverage is required.
  • There is viable but compromised or thin postmastectomy skin flaps that are at risk of dehiscence or necrosis.
  • The inframammary fold and lateral mammary folds have been undermined during mastectomy and reestablishment of these landmarks is needed.

Note: Various acellular dermal matrix products used in breast reconstruction have similar efficacy. The products listed are those that have been identified for use in breast reconstruction. Additional acellular dermal matrix products may become available for this indication.

Treatment of chronic, noninfected, full-thickness diabetic lower extremity ulcers is established when using the following tissue engineered skin substitutes:

  • AlloPatch®a
  • Apligraft®b
  • Dermagraft®b
  • GraftJacket® Regenerative Tissue Matrix-Ulcer Repair
  • Integra®, Omnigraft™ Dermal Regeneration Matrix (also known as Omnigraft™) and Integra Flowable Wound Matrix
  • Theraskin®

Treatment of chronic, noninfected, partial- or full-thickness lower-extremity skin ulcers due to venous insufficiency, which haven’t adequately responded following a one-month period of conventional user therapy is established when using the following tissue-engineered skin substitutes:

  • Aplifraf®b
  • Oasis™ Wound Matrixc
  • Theraskin®

OrCel™ is considered established when all the following criteria are met:

  • Used for the treatment of dystrophic epidermolysis bullosa
  • Used for the treatment of mitten-hand deformity
  • Standard would therapy has failed
  • Provided in accordance with the humanitarian device exemption, or HDE, specifications of the U.S. Food and Drug Administration

The following skin and tissue products and substitutes are considered established for use in the treatment of second- and third-degree burns:

  • Alloderm
  • Epicel® (for the treatment of deep dermal or full-thickness burns comprising a total body surface area ≥30% when provided in accordance with the HDE specifications of the FDA)d
  • Integra® Dermal Regeneration Templateb

aBanked human tissue
bFDA premarket approval
cFDA 510(k) clearance
dFDA-approved under an HDE

Exclusions:

All other uses of bioengineered skin and soft tissue substitutes listed above unless they meet one of the following criteria:

  • FDA approval and provided in accordance with the FDA guidelines
  • Covered by Centers for Medicare & Medicaid Services

All other skin and soft tissue substitutes including, but not limited to:

  • ACell® UBM Hydrated/Lyophilized Wound Dressing
  • AlloSkin™
  • AlloSkin™ RT
  • Aongen™ Collagen Matrix
  • Architect® ECM, PX, FX
  • ArthroFlex™ (Flex Graft)
  • AxoGuard® Nerve Protector (AxoGen)
  • BellaCell HD or SureDerm®
  • CollaCare®
  • CollaCare® Dental
  • Collagen Wound Dressing (Oasis Research)
  • CollaGUARD®
  • CollaMend™
  • CollaWound™
  • Coll-e-Derm
  • Collexa®
  • Collieva®
  • Conexa™
  • Coreleader Colla-Pad
  • CorMatrix®
  • Cymetra™ (Micronized AlloDerm™)
  • Dermadapt™ Wound Dressing
  • DermaPure™
  • DermaSpan™
  • DressSkin
  • Durepair Regeneration Matrix®
  • ENDURAGen™
  • Excellagen
  • ExpressGraft™
  • FlexiGraft®
  • FlowerDerm®
  • GammaGraft
  • hMatrix®
  • InteguPly®
  • Keroxx™
  • MatriDerm®
  • Matrix HD™
  • MemoDerm™
  • Microderm® biologic wound matrix
  • Miroderm®
  • MyOwn Skin™
  • NeoForm™
  • Progenamatrix™
  • Puros® Dermis
  • RegenePro™
  • Repliform®
  • Repriza™
  • SkinTE™
  • SimpliDerm®
  • StrataGraft®
  • TenSIX™ Acellular Dermal Matrix
  • TissueMend
  • TheraForm™ Standard/Sheet
  • TruSkin™
  • Veritas® Collagen Matrix
  • XCM Biologic® Tissue Matrix
  • XenMatrix™ AB

20974, 20975, E0747

Bone growth stimulation for the appendicular skeleton

The safety and efficacy of noninvasive electrical bone growth stimulation have been established. It’s a useful therapeutic option for patients meeting patient selection criteria. 

Inclusionary criteria have been updated, effective March 1, 2023.

Inclusions:

Noninvasive electrical bone growth stimulation can be appropriate for the treatment of nonunions and delayed unions of fractures in the appendicular skeleton. It may also be appropriate for congenital pseudoarthrosis in combination with other treatments. Electrical stimulation in cases of delayed healing of surgical arthrodesis may also be indicated. The appendicular skeleton includes the bones of the shoulder girdle, upper extremities, pelvis and lower extremities. To be an appropriate treatment option all the following criteria must be satisfied:

  • At least three months have passed since the date of fracture (or surgical arthrodesis).
  • Serial radiographs over the most recent three months demonstrate no progressive signs of healing despite appropriate immobilization and protection from weight bearing.
  • The fracture gap is 1 cm or less.
  • The patient’s fracture can be adequately immobilized.
  • Patient is able and willing to comply with all weight bearing restrictions and treatment protocol. 

Exclusions:

All other applications of electrical bone growth simulation including, but not limited to:

  • The immediate post-surgical treatment after appendicular skeletal surgery
  • Stress fractures
  • The treatment of acute fractures. A fracture is most commonly defined as “acute” during the initial seven days after the fracture occurs. Most acute closed fractures heal without complications with the use of standard fracture care, i.e., closed reduction and cast immobilization.
  • Implantable and semi-invasive electrical bone growth stimulators are considered experimental.

20974, 20975, E0748, E0749

    

Basic benefit and medical policy

Bone growth stimulation of the spine

The safety and effectiveness of invasive or noninvasive methods of electrical bone growth stimulation of the spine have been established. They are useful therapeutic options for patients meeting patient selection criteria.

Inclusionary criteria have been updated, effective March 1, 2023.

Inclusions:

  • Invasive or noninvasive methods of electrical bone growth stimulation are medically necessary for use as an adjunct to lumbar or cervical spinal fusion surgery in patients at high risk for fusion failure, defined as any one of the following criteria:
    • One or more previous failed spinal fusions
    • Grade III or worse spondylolisthesis
    • Fusion to be performed at more than one level
    • Current tobacco use
    • Diabetes
    • Renal disease
    • Alcoholism
    • Immunocompromise
    • Systemic vascular disease
    • History of long term use of corticosteroids
    • Metabolic bone disease (including osteoporosis, osteopenia and bone disease secondary to renal disease, nutritional deficiency, or conditions in which bone healing is likely to be compromised)
  • Noninvasive electrical bone stimulation may be considered medically necessary as a treatment of patients with failed lumbar or cervical spinal fusion. Failed spinal fusion is defined as a spinal fusion that hasn’t healed at a minimum of six months after the original surgery, as evidenced by serial X-rays over a course of three months.
Exclusions:

  • Semi-invasive electrical stimulation

54500, 54800, 55300, 58100, 58340, 58345, 58350, 58555, 58558, 58559, 58561, 58660, 58661, 58662, 58740, 58900, 74740, 74742, 80414, 80415, 81224, 82670, 82681, 83001, 83002, 83498, 83727, 84144, 84146, 84402, 84403, 84410, 88230, 88261, 88262, 89300, 89310, 89320, 89321, 89325, 89329, 89330, 89331, G0027

Basic benefit and medical policy

Infertility diagnosis

The safety and effectiveness of diagnostic testing for the evaluation of infertility have been established. These services may be considered useful in the diagnosis of a medical condition that may affect fertility.

Inclusionary and exclusionary criteria have been added, effective March 1, 2023.

Inclusions:

The definition of infertility is considered established in any of the following situations:

  • Opposite-sex partners, when the female partner is younger than age 35, who are unable to achieve conception after 12 months of unprotected intercourse.
  • Opposite-sex partners, when the female partner is age 35 or older, who are unable to achieve conception after six months of unprotected intercourse.
  • A female younger than age 35 who is unable to achieve conception after at least six trials of documented artificial insemination over a consecutive period of 12 months.
  • A female, age 35 or older, who is unable to achieve conception after at least three trials of documented artificial insemination over a consecutive period of six months.

Exclusions:

  • A female, age 35 or older, who is unable to achieve conception after at least three trials of documented artificial insemination over a consecutive period of six months
  • An individual who had a sterilization procedure
  • Opposite-sex partners in which one of the members had a voluntary sterilization procedure (e.g., tubal ligation, vasectomy)
  • An individual age 40 or older whose menses have stopped due to menopause
  • Artificial insemination (donor insemination) isn’t a covered service unless the certificate of coverage or a rider states that it’s a benefit.

55530, 58321, 58322, 58323, 58540,
58672, 58752, 58760, 58970, 58974,
58976, 76857, 76948, 89250, 89253a,
89254, 89255, 89257, 89258, 89259, 89260, 89261, 89264, 89268, 89272, 89280b, 89281b, 89290c, 89291c, 89322, 89335d, 89337a, 89342, 89343, 89344d, 89346a, 89352, 89353, 89354d, 89356a, S4011, S4013, S4014, S4015, S4016, S4021, S4022, S4027, S4028, S4035, S4037, S4040, S4042, J0725             

aOnly when inclusion criteria are met
bOnly for diagnosis of male factor infertility
cRefer to policy “Genetic Testing – Preimplantation”
dOnly for adult men diagnosed with azoospermia, as part of the intracytoplasmic sperm injection procedure.

Not covered:

89251, 89398e, 0253U

    

Basic benefit and medical policy

Assisted reproductive techniques

Selected assisted reproductive techniques, or ART, are established and may be considered useful therapeutic options in the treatment of infertility.

When infertility is due to an underlying medical condition (e.g., chronic infection, uterine fibroids, etc.), the treatment of that disorder is medically necessary and is covered under basic medical-surgical benefits.** When no medically correctable underlying medical condition is found (e.g., low sperm count, anovulation), other options may be pursued. One option is ART – specific services that may be used to establish pregnancy. Assisted reproductive techniques are only available to members when the employer group has chosen to offer the services as additional or extra benefits, through certificate benefit language or riders.

The focus of this policy is the use of ART in individuals who are diagnosed with infertility. Assisted reproductive techniques for individuals who are not diagnosed with infertility is based on benefit coverage (the certificate of coverage or rider) and is beyond the scope of this medical policy. Exclusionary criteria have been updated, effective March 1, 2023. 

**See the medical policy “Infertility Diagnosis.”

Basic benefit policy group variations:

Assisted reproductive techniques, or ARTs, aren’t general medical or surgical benefits. While the procedures listed in the inclusions are considered established, these services are available only as additional benefits offered by a group or employer. The covered services and limitations are defined by the group or employer. The benefit plan, including the certificate of coverage or rider, determines the available coverage.

Inclusions:

  • Artificial insemination
  • Assisted reproductive technologies:
    • In vitro fertilization, or IVF
    • Gamete intrafallopian transfer, or GIFT
    • Transuterine fallopian transfer, or TUFT
    • Natural oocyte retrieval with intravaginal fertilization, or NORIF
    • Pronuclear state tubal transfer, or PROST
    • Tubal embryo transfer, or TET
    • Zygote intrafallopian transfer, or ZIFT
    • Embryo transfer
    • Blastocyst transfer
    • Intracytoplasmic sperm injection, or ICSI, for male factor infertility only
    • Cryopreservation of embryos and sperm
    • Storage of embryos and sperm
    • Thawing of embryos and sperm
    • Mature oocytes: Cryopreservation, with storage and thawing for up to three months following cryopreservation, when both of the following criteria are met:
      • It’s a covered IVF cycle using fresh oocytes
      • Inability to obtain viable sperm for oocyte fertilization at the time of oocyte retrieval
    • Assisted embryo hatching when one of the following criteria is met:
      • The individual is age 38 or older
      • There have been two or more IVF failures related to failed implantation
    • Elective single-embryo transfer, or eSET

Exclusions:

  • Co-culture of embryos
  • Cryopreservation of ovarian tissue, immature oocytes, or testicular tissue**
  • Storage of ovarian tissue or testicular tissue**
  • Thawing of ovarian tissue or testicular tissue**
  • All services related to gestational surrogacy, gestational parent or gestational carrier
  • Time lapse monitoring or imaging of embryos (e.g., EmbryoScope®)
  • Endometrial receptivity testing (e.g., ERA® [Endometrial Receptivity Analysis])
  • ART services are excluded when there has been a voluntary sterilization procedure (e.g., tubal ligation, vasectomy), including when there has been surgical reversal of the sterilization procedure, as this isn’t considered treatment of disease
  • Reversal of prior sterilization procedure is excluded

**Cryopreservation, storage and thawing of testicular tissue is only covered in adult men with azoospermia, as these procedures are part of intracytoplasmic sperm injection.

55873, 55880, 55899**

**Not otherwise classified procedure

Experimental:

0655T

Basic benefit and medical policy

Focal treatments for prostate cancer

Cryoablation of the prostate is considered established as treatment of clinically localized (organ-confined) prostate cancer when performed as initial treatment or as salvage treatment of disease that recurs following radiotherapy when criteria are met.

High-intensity focused ultrasound, or HIFU, ablation of the prostate is considered established as salvage treatment of disease that recurs following radiotherapy, when criteria are met.

Focal laser ablation, radiofrequency ablation and photodynamic therapy for the treatment of localized prostate cancer are considered experimental, as they haven’t been shown to improve patient clinical outcomes.

Exclusionary criteria was updated, effective March 1, 2023.

Inclusions:

Cryoablation may be considered established for the initial treatment of clinically localized (organ-confined) prostate cancer.

Cryoablation or high-intensity focused ultrasound may be considered established for local treatment of recurrent prostate cancer when all the following are met:

  • Primary treatment of prostate cancer was radiation therapy all the following:
    • Original clinical stage T1-T2, NX or N0
    • Life expectancy >10 y
    • PSA now <10 ng/mL
  • Transrectal ultrasound guided biopsy is positive
  • Studies are negative for distant metastases

Exclusions:

  • Local treatment of recurrent prostate cancer that doesn’t meet criteria.
  • Initial treatment of prostate cancer with any of the following: HIFU, focal laser ablation, radiofrequency ablation or photodynamic therapy.    

Focal laser ablation, radiofrequency ablation and photodynamic therapy for the treatment of localized prostate cancer are considered experimental.

77046, 77047, 77048, 77049

    

Basic benefit and medical policy

MRI for breast cancer

The safety and effectiveness of magnetic resonance imaging of the breast have been established. It may be considered a useful diagnostic option for patients meeting criteria.

Inclusionary criteria have been updated, effective March 1, 2023.

Payment policy:

The PPO Radiology Management program applies to these procedures and they may be subject to vendor preauthorization.

Inclusions:

Note: All the following policy statements refer to performing MRI of the breast with a breast coil and the use of contrast. MRI of the breast without the use of a breast coil, regardless of the clinical indication, is considered experimental.

  1. MRI of the breast may be considered established for screening for breast cancer in individuals at a high risk of breast cancer.

High-risk considerations
 
There is no standardized method for determining a woman’s risk of breast cancer that incorporates all possible risk factors. There are validated risk prediction models, but they are based primarily on family history.

The following list includes individual factors known to indicate a high risk of breast cancer:

  • An individual diagnosed with lobular carcinoma in situ, or LCIS, atypical lobular hyperplasia, or ALH/atypical ductal hyperplasia, known as ADH
  • An individual with a known BRCA1 or BRCA2 variant or a first-degree relative of an individual with either of these gene mutations
  • An individual with another gene variant associated with high risk: ATM, BARD 1, CDH1, CHEK2, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53 or a first-degree relative of an individual with any of these gene mutations
  • An individual with a lifetime risk of 20% or greater of developing breast cancer as identified by models that are largely defined by family history. This includes individuals that carry genetic mutations in the following genes: TP53 (Li-Fraumeni syndrome), PTEN (Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome) and STK11 (Peutz-Jeghers syndrome).
  • An individual who received radiotherapy to the chest between 10 and 30 years of age

A number of factors may increase the risk of breast cancer but don’t by themselves indicate high risk. It is possible that combinations of these factors may be indicative of high risk, but it’s not possible to give quantitative estimates of risk. As a result, it may be necessary to individualize the estimate of risk, whereby one would need to take into account the numerous risk factors. A number of risk factors, not individually indicating high risk, are included in the National Cancer Institute Breast Cancer Risk Assessment Tool (also called the Gail model). Risk factors in the model can be accessed online bcrisktool.cancer.gov.

  1. MRI of the breast is considered established for the following indications:

Suspected cancer:

  • Single follow-up MRI at six months following a breast MRI with BI-RADS category 3 findings
  • Differentiation of palpable mass from surgical scar tissue
  • Lesion/abnormality characterization when other imaging (e.g., ultrasound, mammography) and physical examination are inconclusive, and inability to localize the lesion prevents a biopsy from being performed
  • Metastatic cancer of unknown primary and suspected to be of breast origin or axillary adenopathy and no mammographic or physical findings of primary breast carcinoma
  • Evaluation of pathologic nipple discharge after nondiagnostic mammography and ultrasound
  • Suspected breast implant-associated anaplastic large cell lymphoma in patients with textured implants when ultrasound is nondiagnostic
  • Evaluation of a documented abnormality of the breast prior to obtaining an MRI-guided biopsy when there is documentation that other methods, such as palpation or ultrasound, are not able to localize the lesion for biopsy

Diagnostic workup and management:

  • To determine the extent of disease in biopsy-proven breast cancer in either of the following:
    • Ductal carcinoma in situ, or DCIS, when the lesion is greater than 2 cm
    • Invasive carcinoma
  • To define the relationship of the tumor to the fascia and its extension into the pectoralis major, serratus anterior or intercostal muscles prior to surgery
  • Preoperative tumor mapping of the involved breast to evaluate the presence of multicentric disease in patients with clinically localized breast cancer who are candidates for breast-conservation therapy
  • Presurgical planning in patients with locally advanced breast cancer (before and after completion of neoadjuvant chemotherapy) to permit tumor localization and characterization
  • Suspected recurrence in patients with tissue transfer flaps (rectus, latissimus dorsi and gluteal) post-reconstruction
  • Suspected recurrence in patients with a prior history of breast cancer when clinical, mammographic or sonographic findings are inconclusive
  • Post-lumpectomy with close or positive margins to evaluate for residual disease

Surveillance:

  • In patients with a personal history of breast cancer after breast conserving therapy or unilateral mastectomy who meet criteria for MRI breast screening (see Inclusion A)

Exclusions:

  • Screening technique in average-risk patients
  • Screening technique for the detection of breast cancer when the sensitivity of mammography is limited (i.e., dense breasts)
  • Diagnosis of low-suspicion findings on conventional testing, immediate biopsy isn’t indicated, and the patient is referred for short-interval follow-up
  • Diagnosis of a suspicious breast lesion to avoid biopsy

81162-81167, 81212, 81215-81217, 81307, 81308, 81406

Experimental:

81432, 81433, 81479

Basic benefit and medical policy

Germline genetic testing for BRCA1, BRCA2 and PALB2 for hereditary breast/ovarian cancer

The safety and effectiveness of simultaneous testing for inherited BRCA1, BRCA2 and PALB2 variants have been established. It may be considered a useful diagnostic option when indicated for individuals at a high risk of breast or ovarian cancer.

Testing for genomic rearrangements of the BRCA1 and BRCA2 genes (e.g., BART testing) may be considered established in patients who meet criteria for BRCA1 and BRCA2 testing and whose testing for point variants is negative.

Use of multi-gene panels including, but not limited to, BreastNext, OvaNext, BRCAplus, iGene Cancer Panel and BROCA tests is experimental. There is insufficient data on the analytical and clinical validity as well as clinical utility of these tests on patient management and outcomes.

The medical policy statement, and inclusionary and exclusionary criteria have been updated, effective March 1, 2023.

Inclusions:

For purposes of this policy, invasive and ductal carcinoma in situ breast cancers should be included. Testing is clinically indicated in the following scenarios:

  • Individuals with any close blood relative with a known BRCA1, BRCA2 and PALB2 pathogenic or likely pathogenic variant
  • Individuals meeting the criteria below but with previous limited testing (e.g., single gene or absent deletion duplication analysis) who are interested in multi-gene testing
  • Genetic testing for BRCA1, BRCA2 and PALB2 variants in cancer-affected individuals may be considered appropriate under any of the following circumstances:
    • Personal history of epithelial ovarian cancer (including fallopian tube cancer or peritoneal cancer) at any age.
    • Personal history of breast cancer and any of the following:
      • Diagnosed age ≤50 years
      • Diagnosed at any age with any of the following:
        • Treatment indications, any of the following:
          • To aid in systemic treatment decisions using PARP inhibitors for breast cancer in the metastatic setting
          • To aid in adjuvant treatment decisions with olaparib for high-risk, HER2-negative breast cancer
        • Pathology and histology, and of the following:
          • Triple-negative breast cancer
          • Multiple primary breast cancers (synchronous or metachronous)
          • Lobular breast cancer with personal or family history of diffuse gastric cancer
        • Male breast cancer
        • Ashkenazi Jewish ancestry
        • Family history of any of the following:
          • ≥1 close blood relative with any:
            • Breast cancer diagnosed ≤50 years
            • Male breast cancer any age
            • Ovarian cancer any age
            • Prostate cancer with metastatic, or high- or very high-risk group any age
            • Pancreatic cancer any age
          • ≥2 close blood relatives with breast or prostate cancer (any grade) at any age
          • ≥3 total diagnoses of breast cancer in patient or close blood relative
  • Genetic testing for BRCA1, BRCA2 and PALB2 variants of cancer-unaffected individuals may be appropriate under one of the following circumstances:
    • An affected individual not meeting the criteria above or unaffected individual with a first- or second-degree blood relative meeting any of the criteria listed above under “cancer-affected individuals” (except unaffected individuals whose relatives meet criteria only for systemic therapy decision-making). 
      • If the affected relative has pancreatic cancer or prostate cancer, only first-degree relatives should be offered testing unless indicated based on additional family history.
    • An affected individual not meeting the criteria above or unaffected individual who otherwise doesn’t meet the criteria above but has a probability >5% of a BRCA1/2 pathogenic variant based on prior probability models (e.g., Tyrer-Cuzick, BRCAPro, CanRisk).

Exclusions:

  • Patients not meeting any of the above criteria
  • Genetic testing for BRCA1, BRCA2 and PALB2 variants in minors
  • BRCA and BART testing as a screening test for cancer in women in the general population.
  • BRCA and BART testing for unaffected individuals of high-risk populations (e.g., Ashkenazi Jewish descendant) who have no relatives with a history of breast, ovarian, fallopian tube or primary peritoneal cancer at any age.
  • Genetic testing using multi-gene panels including, but not limited to, BreastNext, OvaNext, BRCAplus, iGene Cancer Panel and BROCA tests.

81170, 81206, 81207, 81208, 81401, 81450, 81455, 0016U, 0040U

    

Basic benefit and medical policy

Genetic testing – BCR/ABL1 testing in CML and ALL

The safety and effectiveness of genetic testing for BCR/ABL1 in individuals undergoing evaluation for or diagnosed with chronic myelogenous leukemia, or CML or acute lymphoblastic leukemia, or ALL, have been established. It may be considered a useful tool when indicated.

The medical policy statement and inclusionary criteria have been updated, effective March 1, 2023.

Inclusions:

Chronic myelogenous leukemia
BCR-ABL1 qualitative testing for the presence of the fusion gene is established for the diagnosis of chronic myeloid leukemia.

BCR-ABL1 testing for messenger RNA transcript levels by quantitative real-time reverse transcription-polymerase chain reaction at baseline before initiation of treatment and at appropriate intervals is established for monitoring of chronic myeloid leukemia treatment response and remission.

Evaluation of ABL kinase domain, or KD, single nucleotide variants to assess individuals for tyrosine kinase inhibitor resistance is established when there is an inadequate initial response to treatment or any sign of loss of response, or when there is a progression of the disease to the accelerated or blast phase.

Acute lymphoblastic leukemia
BCR-ABL1 testing for messenger RNA transcript levels by quantitative real-time reverse transcription-polymerase chain reaction at baseline before initiation of treatment and at appropriate intervals during therapy is established for monitoring of Philadelphia chromosome-positive acute lymphoblastic leukemia treatment response and remission.

Evaluation of ABL KD single nucleotide variants to assess individuals for tyrosine kinase inhibitor resistance is established when there is an inadequate initial response to treatment or any sign of loss of response.

Testing:

Next-generation sequencing, or NG, with a multiple-gene panel test (e.g., CPT code *81450 or *81455), may be considered established when used for diagnostic and prognostic purposes or for guidance in the selection of appropriate FDA-approved therapeutic options.

Proprietary laboratory analyses, or PLA, testing
A PLA test as an FDA-approved companion diagnostic to determine the appropriate therapeutic drug is considered established when all the following criteria are met:

  • Biomarker confirmation is required by an FDA-approved or cleared test prior to initiating treatment (as described in the FDA prescribing label of the therapeutic in the section “Indications and Usage”)
  • The test is an FDA-approved companion diagnostic
  • The FDA hasn’t identified a non-PLA test (e.g., an FDA companion diagnostic that is billed by a CPT code) for the same therapeutic indication.

FDA-approved companion diagnostic tests
FDA-approved companion diagnostic tests include:

  • Tests that are billed with CPT codes (most laboratories are able to process these)
  • Proprietary laboratory analyses, or PLA, tests (processed by one specific independent laboratory). Most PLA tests have billing codes that end in “U.”

Exclusions:

BCR/ABL1 testing and Kinase domain mutation testing are considered experimental for all other indications.

81210, 81275, 81276, 81301, 81311, 81403, 81404, 88363, 81210, 0037U, 0111U

Not covered:

86152, 86153, 0239U, 0242U

Basic benefit and medical policy

Somatic biomarker testing in metastatic colorectal cancer

The policy has been updated to cover procedure *0037U when criteria are met, effective Jan. 1, 2023.

The safety and effectiveness of KRAS, NRAS, BRAF, MMR/MSI, HER2 and TMB mutation analyses have been established and may be considered a useful diagnostic option to predict nonresponse to anti-EGFR monoclonal antibodies cetuximab and panitumumab and other categories of therapeutics in the treatment of  patients with metastatic colorectal cancer when indicated. It’s a useful therapeutic option when indicated.

KRAS, NRAS, BRAF, TMB and MSI variant analysis using circulating tumor DNA or circulating tumor cell testing (liquid biopsy) to guide treatment for patients with metastatic colorectal cancer is considered experimental.

Inclusions:

  • KRAS, NRAS and BRAF (V600E) mutation analysis is established in patients with metastatic colorectal cancer in order to determine their nonresponse to EGFR inhibitor drugs such as Vectibix® (panitumumab) and Erbitux® (cetuximab).
  • Human epidermal receptor 2, or HER2, amplification testing is established for patients with metastatic colorectal cancer. Anti-HER2 therapy is only indicated in HER2-ampliified tumors that are also RAS and BRAF wild type. If the tumor is already known to have a KRAS/NRAS or BRAF mutation, HER2 testing isn’t indicated.
  • Mismatch repair/microsatellite instability testing may be considered established for select individuals for treatment with FDA-approved therapies. (Mismatch repair and microsatellite testing of colorectal cancer tissue may be indicated for Lynch syndrome.)
  • TMB testing may be established for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high, or TMB-H, [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options (example, Keytruda).
  • FoundationOne CDx can be used as a companion diagnostic test for MMR and microsatellite instability when above criteria are met.
  • FoundationOne CDx can be used as a companion diagnostic test for TMB when clinically indicated by above criteria when no other therapy options are available.
  • A proprietary laboratory analyses, or PLA, test is considered established when all the following criteria are met:
    • A more targeted test using any methodology isn’t available.
    • The individual meets the FDA criteria listed in the label for the therapeutic.
    • The test is an FDA-approved companion diagnostic test.
    • The FDA hasn’t identified a non-PLA test for the same therapeutic indication.

Exclusions:

  • KRAS, NRAS, BRAF, TMB and MSI variant analysis using circulating tumor DNA (liquid biopsy)

81420, 81507, 81599,** 81479***

Experimental:
81422, 0060U, 0327U

**If the codes above don’t apply and the test involves multianalyte assays and an algorithmic analysis

***If the codes above don’t apply and the test does not involve an algorithmic analysis

Basic benefit and medical policy

Noninvasive prenatal screening for fetal aneuploidies

The safety and effectiveness of noninvasive prenatal screening for fetal aneuploidies using cell-free fetal DNA have been established. It may be considered a useful diagnostic option when indicated.

The peer-reviewed medical literature hasn’t demonstrated the clinical utility of noninvasive prenatal screening for microdeletions and single gene disorders using cell-free fetal DNA. Therefore, this service is considered experimental.

Exclusionary criteria have been updated, effective March 1, 2023.

Inclusions:

  • Nucleic acid sequencing-based testing of maternal plasma to screen for trisomy 21 in women with singleton and twin pregnancies. (Karyotyping would be necessary to exclude the possibility of a false positive nucleic acid sequencing-based test.)
  • Concurrent nucleic acid sequencing-based testing of maternal plasma for trisomy 13 or 18 in women who are eligible for and are undergoing nucleic acid sequencing-based testing of maternal plasma for trisomy 21.  
  • Nucleic acid sequencing-based testing of maternal plasma for fetal sex or fetal sex chromosome aneuploidy only when certain fetal abnormalities are noted on ultrasound, such as cases of ambiguous genitalia or cystic hygroma when the determination of fetal sex is necessary to help guide medical management.

Exclusions:

  • Nucleic acid sequencing-based testing of maternal plasma for trisomy 21 in women with pregnancies of multiple gestations of three or more fetuses
  • Nucleic acid sequencing-based testing of maternal plasma for trisomy 13 or 18, other than in the situations specified above
  • Nucleic acid sequencing-based testing of maternal plasma for fetal sex determination or fetal sex chromosome aneuploidies other than the situation specified above
  • Nucleic acid sequencing-based testing of maternal plasma for microdeletions
  • Nucleic acid sequencing-based testing of maternal plasma for twin zygosity.
  • Vanadis® NIPT of maternal plasma to screen for trisomy 21, 18 and 13
  • Vistara NIPT of maternal plasma to screen for single-gene disorders
  • For other aneuploidies or genetic disorders not specified above

97039,** 97139,** 97799**

**Unlisted procedure code

Basic benefit and medical policy

Alternative physical therapy modalities

The therapy listed in this policy has been determined to be experimental. It isn’t a covered benefit for all contracts that exclude reimbursement for experimental services.

Hako-Med horizontal therapy was added as experimental, effective March 2023.

Inclusions and exclusions:

Not applicable

97129, 97130

Basic benefit and medical policy

Cognitive rehabilitation

The safety and effectiveness of cognitive rehabilitation (as a distinct and definable component of the rehabilitation process) have been established. It may be considered a useful therapeutic option in the rehabilitation of patients meeting specific selection criteria.

Exclusionary criteria have been updated to exclude SARS-CoV-2 infection, effective March 1, 2023.

Inclusions:

Cognitive rehabilitation is an established procedure when used an as adjunctive treatment of cognitive deficits (e.g., attention, language, memory, reasoning, executive functions, problem solving and visual processing) when all the following criteria are met:

  1. The cognitive deficits have been acquired as a result of neurologic impairment due to traumatic brain injury or stroke.
  2. Services must be provided by a qualified licensed professional and must be prescribed by the attending physician as part of the written care plan.
  3. There must be documentation of potential for improvements based on the patient’s pre-injury function.
  4. Patients must be able to actively participate in the program. The patient must have sufficient cognitive function to understand and participate in the program as well as adequate language expression and comprehension (e.g., the patient shouldn’t have severe aphasia).
  5. The member is expected to make significant cognitive improvement (e.g., member isn’t in a vegetative or custodial state).

Exclusions:

Excluded diagnoses include, but are not limited to:

  • Mental retardation
  • Multiple sclerosis
  • Cerebral palsy
  • Encephalopathy
  • S/P brain surgery
  • Dementia (e.g., from Alzheimer’s disease, HIV-infection or Parkinson’s disease)
  • Cognitive decline chronic obstructive pulmonary disease
  • Behavioral or psychiatric disorders such as attention-deficit/hyperactivity disorder and schizophrenia
  • Pervasive developmental disorders
  • Post-acute cognitive sequelae of SARS-CoV-2 infection

J3490

J3590

Basic benefit and medical policy

Aponvie (aprepitant)

Aponvie (aprepitant) is considered established when criteria are met, effective Sept. 16, 2022.

Aponvie (aprepitant) is a substance P/neurokinin-1, or NK1, receptor antagonist, indicated for the prevention of postoperative nausea and vomiting, or PONV, in adults.

Limitations of use:
 
Aponvie (aprepitant) hasn’t been studied for treatment of established nausea and vomiting.

Dosage and administration:
 
The recommended dose is 32 mg administered as a 30 second intravenous injection prior to induction of anesthesia.

Dosage forms and strengths:
                                                                                                                                               
Injectable emulsion: 32 mg/4.4 mL (7.2 mg/mL) in single-dose vial.

Aponvie (aprepitant) isn’t a benefit for URMBT.

J3490

J3590

    

Basic benefit and medical policy

Elucirem (gadopiclenol)

Elucirem (gadopiclenol) is considered established, effective Sept. 21, 2022. 

Elucirem is a gadolinium-based contrast agent indicated in adult and pediatric patients age 2 and older for use with magnetic resonance imaging to detect and visualize lesions with abnormal vascularity in the following:

  • The central nervous system (brain, spine and associated tissues)
  • The body (head and neck, thorax, abdomen, pelvis and musculoskeletal system)

Dosage and administration:

The recommended dose for adult and pediatric patients age 2 and older is 0.05 mmol/kg actual body weight (equivalent to 0.1 mL/kg) administered intravenously at approximately 2 mL/sec.
 
Dosage forms and strengths:

Injection: 0.5 mmol/mL of gadopiclenol in single-dose vials, single-dose prefilled syringes and pharmacy bulk packages.

This drug isn’t a benefit for URMBT.

J3490

J3590

Basic benefit and medical policy

Pedmark (sodium thiosulfate)

Effective Sept. 20, 2022, Pedmark (sodium thiosulfate) is covered for the following FDA-approved indications:

Pedmark is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors.

Limitations of use:

The safety and efficacy of Pedmark haven’t been established when administered following cisplatin infusions longer than six hours. Pedmark may not reduce the risk of ototoxicity when administered following longer cisplatin infusions, because irreversible ototoxicity may have already occurred.

J3490

J3590

    

Basic benefit and medical policy

Testosterone cypionate IM (testosterone cypionate)

Effective June 2, 2022, testosterone cypionate IM (testosterone cypionate) is covered for the following FDA-approved indications:

Testosterone cypionate injection is an androgen indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

Limitations of use:

  • Safety and efficacy of testosterone cypionate injection in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) haven’t been established.
  • Safety and effectiveness in pediatric patients below the age of 12 years haven’t been established.

Dosage and administration:

  • Injectable testosterone products may have different doses, strengths or administration instructions and they aren’t substitutable on a milligram-per-milligram basis. Administer testosterone cypionate injection by deep gluteal intramuscular injection only.
  • Prior to initiating testosterone cypionate injection, confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these serum concentrations are below the normal range.
  • Recommended dosage is 50 mg to 400 mg administered every two to four weeks as a deep intramuscular injection in the gluteal muscle. Individualize the dose and schedule based on the patient’s age, diagnosis, response to treatment and the appearance of adverse reactions.

Dosage forms and strengths:

Injection: 200 mg/mL in a single-dose vial

J3490

J3590

Basic benefit and medical policy

Xenpozyme (olipudase alfa-rpcp)

Effective Aug. 31, 2022, Xenpozyme (olipudase alfa-rpcp) is covered for the following FDA-approved indications:

Xenpozyme (olipudase alfa-rpcp) is a hydrolytic lysosomal sphingomyelin-specific enzyme indicated for treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency, or ASMD, in adult and pediatric patients.

Dosage and administration:

  • Prior to initiating treatment, verify pregnancy status in females of reproductive potential and obtain baseline transaminase levels. 
  • Consider pretreating with antihistamines, antipyretics or corticosteroids.
  • Adults: Recommended starting dose is 0.1 mg/kg administered as an intravenous infusion.
  • Pediatrics: Recommended starting dose is 0.03 mg/kg administered as an intravenous infusion.

Dosage forms and strengths:

For injection: 20 mg of olipudase alfa-rpcp as a lyophilized powder in a single-dose vial for reconstitution

J9173

    

Basic benefit and medical policy

Imfinzi (durvalumab)

The FDA has updated the payable indications for Imfinzi (durvalumab), effective Sept. 2, 2022. The payable indications include the following:

In combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer

None of the information included in this billing chart is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with all applicable state and federal laws and regulations.

Professional

Blue Cross changing practitioner fees July 1

Blue Cross Blue Shield of Michigan will change practitioner fees for services with dates of service on or after July 1, 2023. This change applies to services provided to our Traditional, TRUST and Blue Preferred Plus℠ members, regardless of the customer group.

Blue Cross will use the 2023 Medicare resource-based relative value scale for most relative value unit priced procedures for dates of service on and after July 1. Most fees are currently priced using the 2022 values.

The Blue Cross overall fee update includes base fee adjustments and value-based reimbursement. Due to significant changes in relative value unit valuations, it’s best to review the fee schedule to view the effect on an individual code or group of codes.

Fee schedules effective July 1 will be available on the Provider Resources site through our provider portal on Availity®. To find the fee schedules:

  1. Log in to availity.com.**
  2. Click on Payer Spaces on the menu bar.
  3. Click on the BCBSM and BCN logo.
  4. Scroll down and then click on Secure Provider Resources (Blue Cross and BCN).
  5. Click on the Fee Schedules drop-down menu and then click on Blue Cross Professional Fee Schedules.

Only claims submitted with dates of service on or after July 1 will be reimbursed at the new rates.

Availity is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Blueprint allocation amount of 1.5% to go into effect July 1, 2023

Over the past 18 years, Blue Cross Blue Shield of Michigan has evolved our payment processes to incentivize value over volume. We maintain specific base rates while offering new revenue opportunities through increased incentive payments to health care providers who demonstrate success in delivering care and managing patient health on a population basis. While this pay-for-value approach has improved quality and slowed the rising cost trend, there’s still much work to be done to ensure we can deliver high-quality care that’s affordable for all.

In support of the transition from the fee-for-service model to value-based care, we’ll be introducing a 1.5% allocation from Blue Cross commercial (PPO) professional fees to fund Blueprint risk arrangements for our Blue Cross commercial providers, starting July 1, 2023. These risk arrangements will be partially offset by our annual professional fee schedule update that will also take place starting July 1. 

The 1.5% allocation will be allotted to the Blueprint reward pool and used to reward eligible Risk Bearing Contracted Entities, or RBCEs, for improving the quality of patient care, transforming systems and practices, and reducing costs. Funding the commercial Blueprint incentives through the professional fee schedule is part of the mechanism we use to leverage customer dollars for provider-based incentive programs. 

Physician claim payment vouchers will reflect this change starting July 1, 2023. The vouchers will show the Blueprint allocation amount of 1.5% of the allowed amount, which is based on the Blue Cross commercial applicable fee schedule.

Here are some additional details:

  • All funds from the Blueprint pool, including the allocation and any downside risk payments contributed back to the pool, are distributed to RBCEs that meet targeted commercial performance. 
  • If the entire pool isn’t paid out in a calendar year due to variability in performance, the funds will be retained in the pool for distribution in the following year. If funds do carry over, the 1.5% Blueprint allocation may decrease to account for the retained funds in the Blueprint pool. 
  • No funds in the Blueprint pool will be retained by Blue Cross for administrative costs.

A frequently asked questions document about the Blueprint allocation has been sent to physician organizations and RBCEs for their reference.


AIM changed its name to Carelon

In March 2023, AIM Specialty Health® changed its name to Carelon Medical Benefits Management.
The name change doesn’t affect how the company works with providers. For example:

  • Carelon still manages authorizations for the services they managed before the name change.
  • The company’s provider portal web address didn’t change and providers can access it:
  • The call center numbers are the same:
    • Blue Cross Blue Shield of Michigan: 1-800-728-8008
    • Blue Care Network: 1-844-377-1278
      A recorded message tells callers of the name change to Carelon Medical Benefits Management.
  • Visitors to the AIM Clinical Guidelines** site and corporate webpage** are automatically redirected to a Carelon web address.
  • Clinical decision letters and other communications have transitioned to display the Carelon Medical Benefits Management name and logo.

Note: This is a change only to the AIM Specialty Health name; there are no changes to the way providers submit prior authorization requests.

Carelon Medical Benefits Management (formerly known as AIM Specialty Health) is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to manage authorizations for select services.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Changes to Carelon’s (formerly AIM’s) provider portal for medical oncology program

On May 14, 2023, Carelon Medical Benefits Management (formerly known as AIM Specialty Health®) will release enhancements to the provider portal for the medical oncology program. The goal of the enhancements is to make the process of submitting prior authorization requests easier.

Starting May 14, the look and functionality of the clinical intake screens will change. Among other changes, you’ll notice:

  • An improved look and feel in the case entry screens
  • That biomarker questions are no longer presented for clinical scenarios to which the questions don’t apply
  • That changes to the drug dosing screens make it easier to enter cycle ranges and dates of administration

Register for a webinar to learn more

To learn more about the changes you’ll see when submitting prior authorization requests for medical oncology drugs, register for one of the following webinars, which will be hosted by Carelon. (All times are Eastern time.)

Session type

Day

Date

Time

Registration link

For all providers

Tuesday

May 16, 2023

1 to 2 p.m.

Register

Thursday

Aug. 10, 2023

3 to 4 p.m.

Register

Tuesday

Nov. 14, 2023

3 to 4 p.m.

Register

For Michigan providers who are contracted with Blue Cross Blue Shield of Michigan, Blue Care Network or both
This webinar will be co‑hosted by Blue Cross and BCN.

Tuesday

April 25, 2023

1 to 2 p.m.

Register

Additional information

If you have questions about Carelon’s provider portal or about submitting prior authorization requests for medical oncology drugs, email Carelon at MedicalOncologySolution@aimspecialtyhealth.com.

For more information about the medical oncology program, see the following pages of our ereferrals.bcbsm.com website:

Carelon Medical Benefits Management is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to manage authorizations for select services.


Reminder: Double-check Blue Cross commercial members’ coverage for COVID-19 vaccines

Some Blue Cross Blue Shield of Michigan commercial members have group plans that are exempt from complying with Affordable Care Act requirements. During much of the public health emergency, we covered 100% of the costs for administering COVID-19 vaccines to these members.

Effective April 1, 2023, these members will revert to their pre-pandemic vaccine coverage, unless their group requested otherwise. As a result, they may have out-of-pocket costs or may not have vaccine coverage.

Health care providers should check each Blue Cross commercial member’s eligibility and benefits to determine whether COVID-19 vaccines are a covered benefit.

Notes:

  • When the public health emergency ends May 12, all Blue Cross and BCN members will continue to have COVID-19 vaccine coverage with no out-of-pocket costs if they meet the following criteria:
    • Their plans comply with ACA requirements.
    • Their vaccines are administered by in-network providers or at in‑network pharmacies.
  • When the government-purchased supply of the COVID-19 vaccines runs out, providers should bill the member’s health plan for both administration and the vaccine product. We’ll process claims based on members’ immunization benefits.

Here’s how to check member eligibility and benefits for vaccines:

  1. Log in to our provider portal (availity.com).**
  2. Click on Patient Registration in the menu bar, then click on Eligibility and Benefits Inquiry.
  3. Enter the necessary information in the Payer section and the Provider Information section.
  4. In the Service Information section, enter Immunizations in the Benefit / Service Type field.
  5. Enter the patient ID in the Patient Information section.
  6. Click on Search.
  7. Select the tile for the appropriate member, and click on Submit.
  8. Do one of the following:

If…

Then…

There is a Benefit Explainer button near the top of the screen.

  1. Click on the Benefit Explainer button.
  2. Note: If Benefit Explainer doesn’t open, you’ll need to allow Availity® to open popups.

  3. In Benefit Explainer, click on the Search button.
  4. Press the CTRL and F keys.
  5. Search on Preventive Immunizations.

There isn’t a Benefit Explainer button near the top of the screen.

  1. Click on the Coverage and Benefits tab.
  2. Look in the Immunizations sections.

Availity is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


The Pediatric Place: Creating a centralized hub to facilitate information exchange

Gathering at the start of their workday are, from left, Dr. Nichole Ellis, Jenny Spahr, pediatric nurse practitioner; Cindy Norton, practice manager; Kathy Petersen, family nurse practitioner, and Katie Allwardt, care manager.

This is the first article in a series highlighting some top performers in the Patient-Centered Medical Home Designation Program.

When The Pediatric Place of Hillsdale built a new facility two-and-a-half years ago, they added an island at the center of the exam rooms that the staff calls the “central brain.”

This feature facilitates real-time collaboration and enables the health care team to get a handle on what’s going on with a variety of patients. For example, when the team noticed that many of their patients had the flu recently, they were able to notify the school district promptly.

Pediatric Place, a designated Patient-Centered Medical Home, joined the Collaborative Care Designation Program last year. A nurse from the practice was trained to become the care manager, a position that plays a central role in the collaborative care model.

“As part of our efforts to develop strong relationships with the patients, we thought it was important to have a community and staff member already known by the patients to serve as the care manager,” said practice owner Nichole Ellis, D.O., a medical director with Integrated Health Partners. “Since our nurse began handling care management duties, we’ve seen a significant improvement in patients we’re treating for anxiety and depression.”

To receive CoCM designation, a primary care practice must already have PCMH designation and meet Collaborative Care-specific capabilities. The Pediatric Place has been a PCMH provider for the past 10 years.

Dr. Ellis believes the program has helped improve the value of health care the practice delivers. “The PCMH interpretive guidelines provide a great outline for how to deliver high-quality care, and hold us accountable to ensure we have standardized, documented processes. I really appreciate the way the PCMH program is set up because it allowed us to slowly add more capabilities as we grew, allowing us to see the positive impact this additional support creates for patients.”

Following are a few of the processes that she believes have had the most positive effect on the practice overall:

  • Follow-up after specialist referrals — The staff makes monthly calls to families when a child has been referred to a specialist to ensure that they’ve made an appointment and that it was scheduled in an appropriate time frame.
  • Lab and test tracking — The staff calls families to make sure routine lab testing and other tests were done.
  • Follow-up after emergency department visits — The staff follows up with families when their child has been to the emergency department to schedule a follow-up appointment.
  • Patient education — The staff educates parents about when they might want to make an after-hours call to the provider, helping to avoid unnecessary emergency department visits. Much of the focus is on letting new moms know what type of symptoms warrant an after-hours call.

Cindy Norton, the office manager, has been employed at the practice for nearly 30 years and has served as the office manager for five years. She’s worked closely with the practice’s physician organization, IHP, to implement data registries and other tools to help identify patients who need follow up, and then contacts them to close any gaps in care.

“Consistency and persistence are key to making sure patients get the care they need,” Norton said. “We work hard to ensure that none of our patients fall through the cracks.”

If you’d like to learn more about becoming a PCMH-designated practice, talk with your physician organization or send an email to valuepartnerships@bcbsm.com.


Nonclinical, transitional care program available to Medicare Advantage members outside of Michigan

In 2021, we announced that Blue Cross Blue Shield of Michigan and Blue Care Network had contracted with naviHealth, an independent company, to reduce avoidable inpatient readmissions through a nonclinical, transitional care program.

In March 2023, this program became available to Medicare Plus Blue℠ and BCN Advantage℠ members outside of Michigan when they’re admitted to an acute care hospital and are then discharged to their homes.

This program is currently available to Medicare Plus Blue and BCN Advantage members who are discharged from inpatient acute care facilities in Michigan directly to their homes or to certain post-acute care facilities. To view the list of participating post-acute care facilities, see our Dec. 9 provider alert.

To learn more about the nonclinical, transitional care program, see the November 2021 Record article or the November-December 2021 BCN Provider News article.


2023 brings changes to Total Care Program

Beginning April 7, 2023, Blue Cross Blue Shield of Michigan will be removing Organized Systems of Care from the national Total Care Program as the OSC program no longer offers the incentives required to meet Total Care’s current value-based reimbursement structure.

Total Care is a national designation program that recognizes doctors and hospitals for their efforts in coordinating total patient care, emphasizing prevention and wellness, and helping patients better manage chronic conditions to improve patient outcomes and cost-efficiency. Total Care providers are paid with value-based reimbursement rather than traditional fee-for-service, so they perform against both quality and cost outcome targets to receive incentives and rewards for better health outcomes.

About Organized Systems of Care

An OSC is a community of caregivers that has responsibility for a specific patient population. Blue Cross’ OSC program was initially introduced as an expansion of our Patient-Centered Medical Home program.

If you have any questions about this change, contact Lindsey Novach of National Programs at LNovach@bcbsm.com.


Reminder: New radiology-focused initiative aims to improve quality of care and member outcomes coming soon

As a reminder, Blue Cross Blue Shield of Michigan and Blue Care Network have contracted with Covera Health to launch a radiology-focused quality improvement program to help us better support radiologists and referring providers in their efforts to improve diagnostic quality, overall care and patient outcomes.

This program will start in the second quarter of 2023 for:

  • Commercial members who have coverage through fully insured groups or individual coverage
  • All Medicare Advantage members

For details about the program, see the January issue of The Record or Page 22 of the January-February issue of BCN Provider News.

Note: We previously stated that this program would start in April 2023.

Covera Health is an independent company that supports Blue Cross Blue Shield of Michigan and Blue Care Network by providing programs to help improve the diagnostic quality, quality of care and member outcomes related to radiology.


Reminder: Health care providers must confirm data every 90 days and attest in CAQH every 120 days

What you need to know

To remain listed in Blue Cross Blue Shield of Michigan provider directories, including Find a Doctor, health care providers must re-attest every 120 days.

Have you confirmed data within the past 90 days and attested in CAQH within the past 120 days? If health care providers don’t re-attest with CAQH every 120 days, they won’t be included in Blue Cross Blue Shield of Michigan provider directories. This includes our Find a Doctor search tool. That’s why it’s so important to perform this task.

Here are some other reasons to re-attest with CAQH:

  • Ensure that your affiliation with Blue Cross isn’t interrupted.
  • Keep your contact information up to date.
  • Make sure that claims payment isn’t interrupted.

Regardless of whether providers are practicing at an office location or practicing exclusively in an inpatient hospital setting, they need to perform this attestation.

If you’re practicing exclusively in an inpatient hospital setting, you must indicate it on your CAQH application. This information is used to determine whether full credentialing is required.

CAQH is a nonprofit alliance of health plans and trade associations focused on simplifying health care administration. Blue Cross uses CAQH to gather and coordinate our practitioner credentialing information. All health care practitioners, including hospital-based providers, need to be registered with CAQH.

If you have questions about CAQH, call the help desk at 1-888-599-1771, or go to CAQH.org.**

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Star measure tip sheets updated for 2023

We’ve updated our series of Star Measure Tips  for 2023 and posted them on Availity®. These tip sheets have been developed to assist health care providers and their staff in their efforts to improve overall health care quality for their patients and prevent or control diseases and chronic conditions.

The new tip sheets are current as of this publication. However, when the National Committee for Quality Assurance, or NCQA, publishes final updates to the 2023 HEDIS® specifications, we may need to update the tip sheets again. As updated versions are produced, we’ll post the new ones and announce them in The Record.  

The Star Measure Tips highlight select measures in the Medicare Star Ratings program. Most of the measures featured in the tip sheets are HEDIS measures. HEDIS is one of the most widely used performance improvement tools in the U.S.

Accessing the tip sheets

The Star Measure Tip Sheets are housed on the Secure Provider Resources section of Availity. You can get there by following these steps:

  1. Log in to our provider portal at availity.com.**
  2. Click on Payer Spaces on the Availity menu bar.
  3. Click on the BCBSM and BCN logo
  4. Click on Secure Provider Resources (Blue Cross and BCN) on the Member Care tab and choose Tip Sheets from the drop-down menu.

HEDIS®, which stands for Healthcare Effectiveness Data and Information Set, is a registered trademark of the National Committee for Quality Assurance, or NCQA.

Availity is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Lunch and learn webinars for physicians and coders focus on risk adjustment, coding and documentation

Beginning this month, we’re offering webinars with updated information on documentation and coding common, challenging diagnoses. These live, educational lunchtime sessions also include the opportunity to ask questions. 

Below is our current schedule and the tentative topics for the sessions. All sessions start at noon Eastern time and generally last for 30 minutes.

Session Date

Topic

April 26

HCC and risk adjustment coding scenarios

May 17

Coding neoplasms

June 21

Coding diabetes and hypertension

July 19

Coding heart disease and vascular

Aug. 16

Tips for proper medical record documentation and coding MEAT

Sept. 20

Coding tips for COPD and asthma

Oct. 18

ICD-10-CM updates and changes for 2024

Nov. 15

Coding chronic kidney disease and rheumatoid arthritis

Dec. 13

CPT coding scenarios; a look at the new CPT codes for 2024

Click here if you are already registered for the provider training website. Look in the Event Calendar on the provider training website or use the search feature with the keyword “lunch” to locate all 2023 sessions. Check out the screenshots below to see how the search feature works.

To request access to the provider training website:

  1. Click here to register.
  2. Complete the registration. We recommend using the same email you use to communicate with Blue Cross Blue Shield of Michigan for other needs. This will become your login ID.

If you have any questions about the sessions, contact April Boyce at aboyce@bcbsm.com. If you have questions regarding a session or website registration, email ProviderTraining@bcbsm.com.


Reminder: Register now for 2023 virtual provider symposium sessions

As you may have read in the March Record, this year’s virtual provider symposiums run throughout May and June. Physicians, physician assistants, nurse practitioners, nurses and coders can receive continuing education credits for attending. You’re invited to register for any session listed below.

Click here to log in to the provider training website and register for sessions. If you don’t already have access, you can easily create an account by clicking here. We recommend you use the same email address you use to communicate with Blue Cross Blue Shield of Michigan when creating the account.

Once you’re logged in to the provider training site, open the event calendar to sign up for any of these sessions.

Reach for the Stars-HEDIS®/Star Measure Overview: For physicians and office staff responsible for closing gaps in care related to quality adult measures.

Session

Date

Time

Reach for the Stars-HEDIS®/Star Measure Overview

May 10

9 to 10:30 a.m.

Reach for the Stars-HEDIS®/Star Measure Overview

May 18

12 to 1:30 p.m.

Reach for the Stars-HEDIS®/Star Measure Overview

May 23

2 to 3:30 p.m.

Reach for the Stars-HEDIS®/Star Measure Overview

June 1

8 to 9:30 a.m.

Reach for the Stars-HEDIS®/Star Measure Overview

June 6

12 to 1:30 p.m.

Patient Experience: For physicians and office staff responsible for creating positive patient experiences. Learn how to ensure your practice has the knowledge and tools needed to set and meet patients’ expectations.

Session

Date

Time

Patient Experience — Best Practices for the New Normal

May 2

9 to 10:30 a.m.

Patient Experience — Best Practices for the New Normal

May 9

11:30 a.m. to 1 p.m.

Patient Experience — Best Practices for the New Normal

May 17

12 to 1:30 p.m.

Patient Experience — Best Practices for the New Normal

May 22

2 to 3:30 p.m.

Patient Experience — Best Practices for the New Normal

June 8

9 to 10:30 a.m.

Coding Complex Cases: For physicians, coders, billers and administrative staff

Session

Date

Time

2023 CPT Coding Updates and Coding Complex Cases

May 4

9 to 10 a.m.

2023 CPT Coding Updates and Coding Complex Cases

May 11

12 to 1 p.m.

2023 CPT Coding Updates and Coding Complex Cases

May 16

2 to 3 p.m.

2023 CPT Coding Updates and Coding Complex Cases

June 7

9 to 10 a.m.

2023 CPT Coding Updates and Coding Complex Cases

June 20

12 to 1 p.m.

Questions?

Contact Ellen Kraft at ekraft@bcbsm.com if you have questions about the sessions. Contact the provider training team at ProviderTraining@bcbsm.com if you have questions about registration or using the provider training website.

HEDIS® is a registered trademark of the National Committee for Quality Assurance.

Accreditation statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Minnesota Medical Association and Blue Cross Blue Shields of Michigan. The Minnesota Medical Association (MMA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME statement: The Minnesota Medical Association designates this internet this internet live activity for a maximum of 4 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


We’ve updated our provider training site and changed the platform we use for webinars

Action item

Check out the changes we’ve made to our provider training site and be sure to register for webinars that can support you in your role.

Provider Experience has made a few enhancements to its provider training site and how we host our webinars.

Moving forward, we’ll use the Microsoft Teams webinar platform to host all sessions. Participants with a Teams account will see their Teams ID tracked whenever they join a session. If you don’t have a Teams account, use your full name and email address to sign in.

All webinar events are posted on the provider training website. You can register for sessions as soon as they’re available.

Use the search feature to quickly locate the sessions that work with your schedule. Often, a keyword is all that’s needed to locate the event. For example, a search using the keyword “lunch” will locate the 2023 Lunch and Learn events, as illustrated below.

After the search completes, click on the Events tab to see the full list of sessions.

Click on the event title to register.

Click here if you’re already registered for the provider training website.

Click here to register for the provider training website. We recommend registering under the email you use to communicate with Blue Cross Blue Shield of Michigan and Blue Care Network for other provider-related needs. This will become your login ID.


Resources for prenatal care and well-child visits

This is part of an ongoing series of articles focusing on the tools and resources available to help FEP members manage their health.

The Michigan Quality Improvement Consortium has prenatal care** and routine preventive services for infants and children** guidelines to support health care providers. Here are some additional resources you can use to help educate patients:

  • Routine preventive well-child visits
    • The Centers for Disease Control and Prevention offers multiple resources,** including a Milestone Checklist.**
    • The Healthy Families Program provides tools and resources to help support a healthy lifestyle for FEP members with children of all ages.

FEP member incentives and programs

  • The Pregnancy Care Incentive Program offers expectant Basic and Standard Option members 18 years and older support and rewards during pregnancy.
  • Pregnant FEP members can receive a free blood pressure monitor every two years as part of their maternity benefits. Members can fill out this form and mail it to the address listed.
  • FEP members who are pregnant or nursing can choose from a selection of breast pumps with milk storage bags. FEP members can call 1-800-411-2583 to order a kit.

If you or an FEP member has questions about FEP incentive programs, support services and benefits, call Customer Service at 1-800-482-3600 or go online to fepblue.org.

**Blue Cross and Blue Shield of Michigan doesn’t own or control this website.


Keep your EDI Provider Authorization form updated

Blue Cross Blue Shield of Michigan is dedicated to safeguarding the protected health information of its members. These safeguards include completion of the Trading Partner Agreement and Provider Authorization form as part of the electronic data interchange setup process. All EDI trading partners must complete the TPA and Provider Authorization form before they can exchange PHI with Blue Cross.

The terms of the TPA require you to notify Blue Cross of any changes in your trading partner information, so it’s important to keep your Provider Authorization form up to date. Updating the form also ensures information is routed to the proper destination.

Update the form when you:

  • Change service bureaus or clearinghouses.
  • Change software vendors.
  • Change billing services.
  • Change submitter IDs.
  • Change 835-file recipients.
  • Change unique 835 receivers or trading partner IDs.
  • Decide you no longer want to receive 835 remittance files.

Review the form when you:

  • Join a new group practice.
  • Leave a group practice and start billing using your own NPI.
  • Hire a new billing service.
  • Start submitting claims through a clearinghouse or when you’ve changed clearinghouses.
  • Select a new destination for your 835.

You don’t need to update the Provider Authorization form if your submitter and trading partner IDs don’t change.

How to change your EDI setup:

To make changes to your EDI setup log in to the Trading Partner Agreement webpage.

Or follow the navigation steps to arrive at the TPA login page at bcbsm.com/providers/help/edi:

  1. Visit bcbsm.com/providers.
  2. Click on Help.
  3. Scroll to the Provider online tools section and click on How do I sign up for Electronic Data Interchange?
  4. Click on Trading Partner Agreements.
  5. Click on Complete or Update a Provider Authorization.

If you have any questions about EDI enrollment, contact the EDI Help Desk at EDISupport@bcbsm.com. Include your billing NPI and submitter ID with all correspondence.

Facility

Ambulatory surgery facilities can submit application to join Blue High Performance Network

Action item

To receive a copy of the full criteria and application instructions for the BlueHPN, contact the BlueHPN team at BlueHPN@bcbsm.com

As we informed you in the November 2022 Record article “Submit application to join Blue High Performance Network,” Blue Cross Blue Shield of Michigan has opened applications to hospital systems, their physician partners and other types of health care providers for the Detroit-area Blue High Performance Network℠, or BlueHPN. Criteria and participation status will be effective, starting Jan. 1, 2024.

Blue Cross has updated the criteria for ambulatory surgery facilities to participate in the Detroit-area BlueHPN. We’ll select health care providers based the criteria outlined in the BlueHPN Request for Applications.

To be eligible for the network, ambulatory surgery facilities must:

  • Be located in and provide services to Blue Cross members in Genesee, Macomb, Oakland, St. Clair, Washtenaw and Wayne counties
  • Meet all Blue Cross credentialing and privileging standards, and be in good standing in the TRUST PPO or Traditional network, depending on the provider type
  • Agree to achieve and maintain quality performance measures as illustrated in the Request for Applications
  • Not be affiliated with a non-Blue High Performance Network hospital system

To receive a copy of the full criteria and application instructions for the BlueHPN, email BlueHPN@bcbsm.com.


We’re updating our ambulatory surgery facility incentive model for CQI participation

In mid-2023, Blue Cross Blue Shield of Michigan and Blue Care Network will make updates to the ambulatory surgery facilities Collaborative Quality Initiatives model. We’ll introduce additional incentives for ASFs that participate in more than one CQI, as well as a performance-based incentive.

We introduced these changes to the participating ASFs in March 2023 and plan to roll out a portion of the new incentives in June 2023. Details of these changes will be updated in the ASF CQI Program guide by June 2023. 

Background

In late 2020, Blue Cross introduced the first incentive model for ambulatory surgery facilities participating in our CQIs. This incentive, introduced as a 1% facility fee increase, supports ASF’s clinical data abstraction and reporting, as well as the development of a quality initiatives infrastructure to support CQI operations and implementation of quality initiatives interventions. Qualifying ASFs participating in either the Michigan Arthroplasty Registry CQI, known as MARCQI, or the Michigan Spine Surgery Improvement Collaborative, known as MSSIC, are eligible to receive this incentive.

Additional information

For more information, refer to our provider manual or reach out to your provider consultant. To access the provider manual through our provider portal:

  1. Log in to availity.com.**
  2. Click on Payer Spaces on the Availity® menu bar.
  3. Click on the BCBSM and BCN logo.
  4. Click on Provider manuals under the Resources tab.

ASFs that are interested in participating in the CQI program can email CQIprograms@bcbsm.com for additional details.

Availity is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Unconscious bias training needed to be eligible for designation as Blue Distinction Center for Maternity Care

As you’ve read in previous articles in our provider publications, Blue Cross Blue Shield of Michigan is adding an unconscious bias education requirement as part of our local plan criteria for the Blue Distinction® Centers for Maternity Care program. 

This aligns with the Blue Cross and Blue Shield Association’s efforts to support maternal health equity actions, as well as Blue Cross Blue Shield of Michigan’s commitment to developing a robust maternal health strategy. Our strategy is intended to enhance the experience of members seeking to build families, improve clinical outcomes for mothers and babies, and eliminate maternal health disparities. 

To be eligible for designation, with a Jan. 1, 2024, effective date, all physicians and certified nurse midwives (both hospital-based and those with hospital privileges) who deliver babies at the applicant facility must have completed unconscious bias education by June 1, 2023. If training is completed after June 1, the effective date of designation may be delayed.

The following providers are excluded from this requirement:

  • Physicians and CNMs who aren’t currently practicing at the applicant facility at the time of the application’s submission (for example, those who have retired or left employment at the facility)
  • Physician assistants, nurse practitioners and medical or surgical residents in training
  • Emergency room physicians
  • Locum tenens physicians and temporary CNMs
  • Obstetric hospitalists and laborists

Applying facilities must attest to completion of an education program through a Blue Cross Blue Shield of Michigan survey that will be administered by email. If a provider fails to complete unconscious bias education, then the provider will be considered “not eligible” for BDC status. This will result in the denial or loss of designation as a Blue Distinction Center for Maternity Care.

Unconscious bias education completed within the past 12 months will be accepted as satisfying this requirement. The recommended free online courses listed below are available to those who have not yet completed their training.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Change Healthcare portal created to help providers import medical records

Change Healthcare now offers eligible providers access to an online portal that allows the secure upload of requested medical records for the EquiClaim retrospective audits. EquiClaim is an independent company that provides auditing support for Blue Cross Blue Shield of Michigan and Blue Care Network conducting medical claim audits for our members.

As of January 2023, the portal allows for the submission of medical records only. Change Healthcare is working to expand the ability to upload other types of documents, such as appeals. The portal is protected health information-friendly and HIPPA compliant. It allows users to securely submit medical records to Change Healthcare at no cost to them.

Change Healthcare has an agreement with copy service vendor MRO that excludes providers from using the portal if they’re already in a contract with MRO.

How to register for the portal

Register for portal access using this link:**

  • Select Medical Attachments when prompted on the Product & Services Selection page. Untick the solution on the left side.
  • You’ll receive a confirmation page once you fill out the facility information; wait 5 to 6 business days for completion. You’ll receive a follow-up email with more steps to set a password for your secure account.

Portal instructions

You can access the Change Healthcare Attachments Solution at attachments.changehealthcare.com/payment-integrity.**

  1. Enter the email address registered to account.
  2. Click on the link for Payment Integrity on the bottom right corner of the page or select Payment Integrity from the Menu heading in the top left corner of the screen.
  3. Enter the Case ID for the documents you’ll be uploading.
    • Case ID can be found on the Medical Records Request letter.
    • Case ID will be 12 characters in length.
  4. Click on Add Files to select with documents to upload.
  5. Click on Submit.

Questions?

If you have questions or need technical assistance, call 1-866-943-9579, option 1, from 8 a.m. to 4:30 p.m. Eastern time, Monday through Thursday. Please have your Tax Identification Number ready to provide to your support team member.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


Submit prior authorization requests for human organ transplants through e-referral, not fax, starting June 1

Beginning June 1, 2023, we’ll require providers located in Michigan to submit prior authorization requests for human organ transplant procedures through the e-referral system and not by fax.

This applies to requests for Blue Cross Blue Shield of Michigan commercial, Blue Care Network commercial and BCN Advantage℠ members having bone marrow and specified solid organ transplant procedures.

This change doesn’t apply to Medicare Plus Blue℠ members.

Also, it doesn’t include kidney transplant procedures except for Blue Cross and Blue Shield Federal Employee Program® members, for whom kidney transplant procedures require prior authorization.

Currently, most providers are faxing these requests to us.

Notice for hospital transplant financial coordinators

To prepare for this change, hospital transplant financial coordinators must contact their Availity® administrator so the administrator can:

  • Give the coordinator access to our provider portal (availity.com).**
  • Set up the e-referral tool within Availity for the coordinator.

We’ll contact each coordinator by email to help them determine who their Availity administrator is. In addition, we’ll schedule webinars in May so the coordinators can learn how to use the e-referral system.

We’ll notify the coordinators directly about registering for the webinars.

Availity is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


AIM changed its name to Carelon

In March 2023, AIM Specialty Health® changed its name to Carelon Medical Benefits Management.
The name change doesn’t affect how the company works with providers. For example:

  • Carelon still manages authorizations for the services they managed before the name change.
  • The company’s provider portal web address didn’t change and providers can access it:
  • The call center numbers are the same:
    • Blue Cross Blue Shield of Michigan: 1-800-728-8008
    • Blue Care Network: 1-844-377-1278
      A recorded message tells callers of the name change to Carelon Medical Benefits Management.
  • Visitors to the AIM Clinical Guidelines** site and corporate webpage** are automatically redirected to a Carelon web address.
  • Clinical decision letters and other communications have transitioned to display the Carelon Medical Benefits Management name and logo.

Note: This is a change only to the AIM Specialty Health name; there are no changes to the way providers submit prior authorization requests.

Carelon Medical Benefits Management (formerly known as AIM Specialty Health) is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to manage authorizations for select services.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Changes to Carelon’s (formerly AIM’s) provider portal for medical oncology program

On May 14, 2023, Carelon Medical Benefits Management (formerly known as AIM Specialty Health®) will release enhancements to the provider portal for the medical oncology program. The goal of the enhancements is to make the process of submitting prior authorization requests easier.

Starting May 14, the look and functionality of the clinical intake screens will change. Among other changes, you’ll notice:

  • An improved look and feel in the case entry screens
  • That biomarker questions are no longer presented for clinical scenarios to which the questions don’t apply
  • That changes to the drug dosing screens make it easier to enter cycle ranges and dates of administration

Register for a webinar to learn more

To learn more about the changes you’ll see when submitting prior authorization requests for medical oncology drugs, register for one of the following webinars, which will be hosted by Carelon. (All times are Eastern time.)

Session type

Day

Date

Time

Registration link

For all providers

Tuesday

May 16, 2023

1 to 2 p.m.

Register

Thursday

Aug. 10, 2023

3 to 4 p.m.

Register

Tuesday

Nov. 14, 2023

3 to 4 p.m.

Register

For Michigan providers who are contracted with Blue Cross Blue Shield of Michigan, Blue Care Network or both
This webinar will be co‑hosted by Blue Cross and BCN.

Tuesday

April 25, 2023

1 to 2 p.m.

Register

Additional information

If you have questions about Carelon’s provider portal or about submitting prior authorization requests for medical oncology drugs, email Carelon at MedicalOncologySolution@aimspecialtyhealth.com.

For more information about the medical oncology program, see the following pages of our ereferrals.bcbsm.com website:

Carelon Medical Benefits Management is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to manage authorizations for select services.


Reminder: Double-check Blue Cross commercial members’ coverage for COVID-19 vaccines

Some Blue Cross Blue Shield of Michigan commercial members have group plans that are exempt from complying with Affordable Care Act requirements. During much of the public health emergency, we covered 100% of the costs for administering COVID-19 vaccines to these members.

Effective April 1, 2023, these members will revert to their pre-pandemic vaccine coverage, unless their group requested otherwise. As a result, they may have out-of-pocket costs or may not have vaccine coverage.

Health care providers should check each Blue Cross commercial member’s eligibility and benefits to determine whether COVID-19 vaccines are a covered benefit.

Notes:

  • When the public health emergency ends May 12, all Blue Cross and BCN members will continue to have COVID-19 vaccine coverage with no out-of-pocket costs if they meet the following criteria:
    • Their plans comply with ACA requirements.
    • Their vaccines are administered by in-network providers or at in‑network pharmacies.
  • When the government-purchased supply of the COVID-19 vaccines runs out, providers should bill the member’s health plan for both administration and the vaccine product. We’ll process claims based on members’ immunization benefits.

Here’s how to check member eligibility and benefits for vaccines:

  1. Log in to our provider portal (availity.com).**
  2. Click on Patient Registration in the menu bar, then click on Eligibility and Benefits Inquiry.
  3. Enter the necessary information in the Payer section and the Provider Information section.
  4. In the Service Information section, enter Immunizations in the Benefit / Service Type field.
  5. Enter the patient ID in the Patient Information section.
  6. Click on Search.
  7. Select the tile for the appropriate member, and click on Submit.
  8. Do one of the following:

If…

Then…

There is a Benefit Explainer button near the top of the screen.

  1. Click on the Benefit Explainer button.
  2. Note: If Benefit Explainer doesn’t open, you’ll need to allow Availity® to open popups.

  3. In Benefit Explainer, click on the Search button.
  4. Press the CTRL and F keys.
  5. Search on Preventive Immunizations.

There isn’t a Benefit Explainer button near the top of the screen.

  1. Click on the Coverage and Benefits tab.
  2. Look in the Immunizations sections.

Availity is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


Nonclinical, transitional care program available to Medicare Advantage members outside of Michigan

In 2021, we announced that Blue Cross Blue Shield of Michigan and Blue Care Network had contracted with naviHealth, an independent company, to reduce avoidable inpatient readmissions through a nonclinical, transitional care program.

In March 2023, this program became available to Medicare Plus Blue℠ and BCN Advantage℠ members outside of Michigan when they’re admitted to an acute care hospital and are then discharged to their homes.

This program is currently available to Medicare Plus Blue and BCN Advantage members who are discharged from inpatient acute care facilities in Michigan directly to their homes or to certain post-acute care facilities. To view the list of participating post-acute care facilities, see our Dec. 9 provider alert.

To learn more about the nonclinical, transitional care program, see the November 2021 Record article or the November-December 2021 BCN Provider News article.


Reminder: New radiology-focused initiative aims to improve quality of care and member outcomes coming soon

As a reminder, Blue Cross Blue Shield of Michigan and Blue Care Network have contracted with Covera Health to launch a radiology-focused quality improvement program to help us better support radiologists and referring providers in their efforts to improve diagnostic quality, overall care and patient outcomes.

This program will start in the second quarter of 2023 for:

  • Commercial members who have coverage through fully insured groups or individual coverage
  • All Medicare Advantage members

For details about the program, see the January issue of The Record or Page 22 of the January-February issue of BCN Provider News.

Note: We previously stated that this program would start in April 2023.

Covera Health is an independent company that supports Blue Cross Blue Shield of Michigan and Blue Care Network by providing programs to help improve the diagnostic quality, quality of care and member outcomes related to radiology.


Lunch and learn webinars for physicians and coders focus on risk adjustment, coding and documentation

Beginning this month, we’re offering webinars with updated information on documentation and coding common, challenging diagnoses. These live, educational lunchtime sessions also include the opportunity to ask questions. 

Below is our current schedule and the tentative topics for the sessions. All sessions start at noon Eastern time and generally last for 30 minutes.

Session Date

Topic

April 26

HCC and risk adjustment coding scenarios

May 17

Coding neoplasms

June 21

Coding diabetes and hypertension

July 19

Coding heart disease and vascular

Aug. 16

Tips for proper medical record documentation and coding MEAT

Sept. 20

Coding tips for COPD and asthma

Oct. 18

ICD-10-CM updates and changes for 2024

Nov. 15

Coding chronic kidney disease and rheumatoid arthritis

Dec. 13

CPT coding scenarios; a look at the new CPT codes for 2024

Click here if you are already registered for the provider training website. Look in the Event Calendar on the provider training website or use the search feature with the keyword “lunch” to locate all 2023 sessions. Check out the screenshots below to see how the search feature works.

To request access to the provider training website:

  1. Click here to register.
  2. Complete the registration. We recommend using the same email you use to communicate with Blue Cross Blue Shield of Michigan for other needs. This will become your login ID.

If you have any questions about the sessions, contact April Boyce at aboyce@bcbsm.com. If you have questions regarding a session or website registration, email ProviderTraining@bcbsm.com.


We’ve updated our provider training site and changed the platform we use for webinars

Action item

Check out the changes we’ve made to our provider training site and be sure to register for webinars that can support you in your role.

Provider Experience has made a few enhancements to its provider training site and how we host our webinars.

Moving forward, we’ll use the Microsoft Teams webinar platform to host all sessions. Participants with a Teams account will see their Teams ID tracked whenever they join a session. If you don’t have a Teams account, use your full name and email address to sign in.

All webinar events are posted on the provider training website. You can register for sessions as soon as they’re available.

Use the search feature to quickly locate the sessions that work with your schedule. Often, a keyword is all that’s needed to locate the event. For example, a search using the keyword “lunch” will locate the 2023 Lunch and Learn events, as illustrated below.

After the search completes, click on the Events tab to see the full list of sessions.

Click on the event title to register.

Click here if you’re already registered for the provider training website.

Click here to register for the provider training website. We recommend registering under the email you use to communicate with Blue Cross Blue Shield of Michigan and Blue Care Network for other provider-related needs. This will become your login ID.


Keep your EDI Provider Authorization form updated

Blue Cross Blue Shield of Michigan is dedicated to safeguarding the protected health information of its members. These safeguards include completion of the Trading Partner Agreement and Provider Authorization form as part of the electronic data interchange setup process. All EDI trading partners must complete the TPA and Provider Authorization form before they can exchange PHI with Blue Cross.

The terms of the TPA require you to notify Blue Cross of any changes in your trading partner information, so it’s important to keep your Provider Authorization form up to date. Updating the form also ensures information is routed to the proper destination.

Update the form when you:

  • Change service bureaus or clearinghouses.
  • Change software vendors.
  • Change billing services.
  • Change submitter IDs.
  • Change 835-file recipients.
  • Change unique 835 receivers or trading partner IDs.
  • Decide you no longer want to receive 835 remittance files.

Review the form when you:

  • Join a new group practice.
  • Leave a group practice and start billing using your own NPI.
  • Hire a new billing service.
  • Start submitting claims through a clearinghouse or when you’ve changed clearinghouses.
  • Select a new destination for your 835.

You don’t need to update the Provider Authorization form if your submitter and trading partner IDs don’t change.

How to change your EDI setup:

To make changes to your EDI setup log in to the Trading Partner Agreement webpage.

Or follow the navigation steps to arrive at the TPA login page at bcbsm.com/providers/help/edi:

  1. Visit bcbsm.com/providers.
  2. Click on Help.
  3. Scroll to the Provider online tools section and click on How do I sign up for Electronic Data Interchange?
  4. Click on Trading Partner Agreements.
  5. Click on Complete or Update a Provider Authorization.

If you have any questions about EDI enrollment, contact the EDI Help Desk at EDISupport@bcbsm.com. Include your billing NPI and submitter ID with all correspondence.

No portion of this publication may be copied without the express written permission of Blue Cross Blue Shield of Michigan, except that BCBSM participating health care providers may make copies for their personal use. In no event may any portion of this publication be copied or reprinted and used for commercial purposes by any party other than BCBSM.

*CPT codes, descriptions and two-digit numeric modifiers only are copyright 2022 American Medical Association. All rights reserved.